<SEC-DOCUMENT>0001193125-22-186433.txt : 20220701
<SEC-HEADER>0001193125-22-186433.hdr.sgml : 20220701
<ACCEPTANCE-DATETIME>20220630205903
ACCESSION NUMBER:		0001193125-22-186433
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20220628
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220701
DATE AS OF CHANGE:		20220630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			89bio, Inc.
		CENTRAL INDEX KEY:			0001785173
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831114349
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39122
		FILM NUMBER:		221059295

	BUSINESS ADDRESS:	
		STREET 1:		142 SANSOME STREET
		STREET 2:		SECOND FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104
		BUSINESS PHONE:		(415) 432-9270

	MAIL ADDRESS:	
		STREET 1:		142 SANSOME STREET
		STREET 2:		SECOND FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d376547d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:etnb="http://www.89bio.com/20220628" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-06-28_to_2022-06-28">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-06-28_to_2022-06-28">0001785173</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="etnb-20220628.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-06-28_to_2022-06-28"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001785173</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-28</xbrli:startDate> <xbrli:endDate>2022-06-28</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-06-28_to_2022-06-28">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-06-28_to_2022-06-28" format="ixt:datemonthdayyearen">June 28, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-06-28_to_2022-06-28">89bio, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-06-28_to_2022-06-28" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-06-28_to_2022-06-28">001-39122</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-06-28_to_2022-06-28">36-4946844</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-06-28_to_2022-06-28">142 Sansome Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-06-28_to_2022-06-28">Second Floor</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-06-28_to_2022-06-28">San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-06-28_to_2022-06-28">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-06-28_to_2022-06-28">94104</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-06-28_to_2022-06-28">(415)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-06-28_to_2022-06-28">432-9270</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-06-28_to_2022-06-28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-06-28_to_2022-06-28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-06-28_to_2022-06-28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-06-28_to_2022-06-28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-06-28_to_2022-06-28">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-06-28_to_2022-06-28">ETNB</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-06-28_to_2022-06-28" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-06-28_to_2022-06-28" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2022-06-28_to_2022-06-28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2022, 89bio, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (&#8220;Underwriting Agreement&#8221;) with BofA Securities, Inc. and SVB Securities, LLC, as the representatives of the underwriters named therein (the &#8220;Underwriters&#8221;), to issue and sell 18,675,466 shares of the Company&#8217;s common stock and accompanying warrants to acquire 9,337,733 shares of the Company&#8217;s common stock (the &#8220;Warrants&#8221;) at a combined public offering price of $3.55 and, in lieu of common stock to certain investors, <span style="white-space:nowrap">pre-funded</span> warrants to purchase 7,944,252 shares of common stock (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;) and accompanying Warrants to purchase up to 3,972,126 shares of common stock at a combined public offering price of $3.549 per share, which represents the combined public offering price for a share of common stock and accompanying warrant, less the $0.001 per share exercise price for each <span style="white-space:nowrap">Pre-Funded</span> Warrant (the &#8220;Offering&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrants have an exercise price of $5.325 per share, are exercisable immediately, and will expire two years following the date of issuance. The <span style="white-space:nowrap">Pre-Funded</span> Warrants are exercisable at any time after the date of issuance. A holder of Warrants or <span style="white-space:nowrap">Pre-Funded</span> Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% or 9.99%, as applicable, of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of Warrants or <span style="white-space:nowrap">Pre-Funded</span> Warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The gross proceeds from the Offering are approximately $94.5&#160;million before deducting customary underwriting discounts and offering expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above were offered pursuant to a shelf registration statement (File <span style="white-space:nowrap">No.&#160;333-254684),</span> which became effective on April&#160;23, 2021. A final prospectus supplement dated June&#160;28, 2022 relating to and describing the terms of the Offering was filed with the U.S. Securities and Exchange Commission on June&#160;30, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Underwriting Agreement, the Company agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute payments that the underwriters may be required to make because of such liabilities. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Underwriting Agreement, the form of Warrant and the form of Pre-Funded Warrant are filed as Exhibits 1.1, 4.1 and 4.2, respectively, and are incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement, the Warrants and Pre-Funded Warrants do not purport to be complete and are qualified in its entirety by reference to such exhibit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the opinion of Gibson, Dunn&#160;&amp; Crutcher LLP relating to the validity of the issuance and sale of the shares of the common stock, the Warrants and Pre-Funded Warrants in the Offering is filed herewith as Exhibit 5.1. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d376547dex11.htm">89bio, Inc. Underwriting Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d376547dex41.htm">Form of Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d376547dex42.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d376547dex51.htm">Opinion of Gibson, Dunn&#160;&amp; Crutcher LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d376547dex51.htm">Consent of Gibson, Dunn&#160;&amp; Crutcher LLP (included in Exhibit&#160;5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The cover page from the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> formatted in Inline XBRL.</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3">Date: June&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">89bio, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rohan Palekar</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Rohan Palekar</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d376547dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89BIO, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware
corporation) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18,675,466 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7,944,252 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 7,944,252 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26,619,718 Common Warrants to Purchase 13,309,859 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>UNDERWRITING AGREEMENT </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:
June&nbsp;28, 2022 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89BIO, INC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware corporation) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18,675,466 Shares of Common Stock </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7,944,252 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 7,944,252 Shares of Common Stock </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26,619,718 Common Warrants to Purchase 13,309,859 Shares of Common Stock </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">June&nbsp;28, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB Securities LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">as Representatives of the
several Underwriters </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BofA Securities, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">One Bryant Park </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10036 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SVB Securities LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1301 Avenue of the Americas, 12th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">89bio, Inc., a Delaware corporation (the &#147;Company&#148;), confirms its agreement with BofA Securities, Inc. (&#147;BofA&#148;) and
SVB Securities LLC (&#147;SVB Securities&#148;) and each of the other Underwriters named in <U>Schedule A</U> hereto (collectively, the &#147;Underwriters,&#148; which term shall also include any underwriter substituted as hereinafter provided in
Section&nbsp;10 hereof), for whom BofA and SVB Securities are acting as representatives (in such capacity, the &#147;Representatives&#148;), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not
jointly, of the respective numbers of (i)&nbsp;shares of Common Stock, par value $0.001 per share, of the Company (&#147;Common Stock&#148;), (ii) <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in the form set forth in Exhibit B hereto
to purchase shares of Common Stock (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;), and (iii)&nbsp;common warrants in the form set forth in <U>Exhibit C</U> hereto to purchase shares of Common Stock (the &#147;Common
Warrants&#148; and, together with the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the &#147;Warrants&#148;), each as set forth in <U>Schedule A</U> hereto. The aforesaid 18,675,466 shares of Common Stock (the &#147;Shares&#148;),
7,944,252 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase 7,944,252 shares of Common Stock and 26,619,718 Common Warrants to purchase 13,309,859 shares of Common Stock to be purchased by the Underwriters are herein called,
collectively, the &#147;Securities&#148; and the shares of Common Stock issuable upon exercise of the Warrants are herein called the &#147;Warrant Shares&#148;. Each Share is being sold together with one Common Warrant and each <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant is being sold together with one Common Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company understands that the
Underwriters propose to make a public offering of the Securities as soon as the Representatives deem advisable after this Agreement has been executed and delivered. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has filed with the Securities and Exchange Commission (the
&#147;Commission&#148;) a shelf registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-254684),</FONT> covering the public offering and sale of certain securities, including the
Securities, under the Securities Act of 1933, as amended (the &#147;1933 Act&#148;), and the rules and regulations promulgated thereunder (the &#147;1933 Act Regulations&#148;), which such registration statement was declared effective by the
Commission on April&nbsp;23, 2021. Such registration statement, as of any time, means such registration statement as amended by any post-effective amendments thereto to such time, including the exhibits and any schedules thereto at such time, the
documents incorporated or deemed to be incorporated by reference therein at such time pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time
pursuant to Rule 430B under the 1933 Act Regulations (&#147;Rule 430B&#148;), is referred to herein as the &#147;Registration Statement;&#148; provided, however, that the &#147;Registration Statement&#148; without reference to a time means such
registration statement as amended by any post-effective amendments thereto as of the time of the first contract of sale for the Securities, which time shall be considered the &#147;new effective date&#148; of such registration statement with respect
to the Securities within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and schedules thereto as of such time, the documents incorporated or deemed incorporated by reference therein at such time pursuant to Item 12 of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to the Rule 430B. Each preliminary prospectus used in connection with the offering of the Securities, including
the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act, are collectively referred to herein as a &#147;preliminary prospectus.&#148;
Promptly after execution and delivery of this Agreement, the Company will prepare and file a final prospectus relating to the Securities in accordance with the provisions of Rule 424(b) under the 1933 Act Regulations (&#147;Rule 424(b)&#148;).The
final prospectus, in the form first furnished or made available to the Underwriters for use in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12
of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act, are collectively referred to herein as the &#147;Prospectus.&#148; For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the
Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system or any successor system (&#147;EDGAR&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;1934 Act&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;1934 Act Regulations&#148; means the rules and regulations of the Commission under the 1934 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 6:30 p.m., New York City time, on June&nbsp;28, 2022 or such other time as agreed by the
Company and BofA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;General Disclosure Package&#148; means any Issuer General Use Free Writing Prospectuses issued at
or prior to the Applicable Time, the most recent preliminary prospectus (including any documents incorporated therein by reference) that is distributed to investors prior to the Applicable Time and the information included on <U>Schedule <FONT
STYLE="white-space:nowrap">B-1</FONT></U> hereto, all considered together. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer Free Writing Prospectus&#148;
means any &#147;issuer free writing prospectus,&#148; as defined in Rule 433 of the 1933 Act Regulations (&#147;Rule 433&#148;), including without limitation any &#147;free writing prospectus&#148; (as defined in Rule 405 of the 1933 Act Regulations
(&#147;Rule 405&#148;)) relating to the Securities that is (i)&nbsp;required to be filed with the Commission by the Company, (ii)&nbsp;a &#147;road show that is a written communication&#148; within the meaning of Rule 433(d)(8)(i), whether or not
required to be filed with the Commission, or (iii)&nbsp;exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case,
in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#146;s records pursuant to Rule 433(g). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer General Use Free Writing Prospectus&#148; means any Issuer Free
Writing Prospectus that is intended for general distribution to prospective investors (other than a &#147;<I>bona fide</I> electronic road show,&#148; as defined in Rule 433), as evidenced by its being specified in <U>Schedule <FONT
STYLE="white-space:nowrap">B-2</FONT></U> hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer Limited Use Free Writing Prospectus&#148; means any Issuer
Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d) of the 1933 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the 1933 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to financial statements and schedules and other information which is &#147;contained,&#148;
&#147;included&#148; or &#147;stated&#148; in the Registration Statement, any preliminary prospectus or the Prospectus (or other references of like import) shall be deemed to include all such financial statements and schedules and other information
incorporated or deemed incorporated by reference in or otherwise deemed by 1933 Act Regulations to be a part of or included in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and
delivery of this Agreement; and all references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document under the 1934 Act, which
is incorporated or deemed to be incorporated by reference in or otherwise deemed by 1933 Act Regulations to be a part of or included in the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the
execution and delivery of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Representations and Warranties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Representations and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the date hereof, the
Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Registration Statement</U><U> and Prospectuses</U>. The Company meets the requirements for use of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act. Each of the Registration Statement and any post-effective amendment thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement
or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued by the Commission and no proceedings for any of those purposes have
been instituted or are pending or, to the Company&#146;s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Registration Statement and any post-effective amendment thereto, at the time of its effectiveness, each deemed
effective date with respect to the Underwriters pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, the Applicable Time, the Closing Time and any Date of Delivery complied and will comply in all material respects with the requirements of the
1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, and, in each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
case, at the Applicable Time, the Closing Time and any Date of Delivery complied and will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each
preliminary prospectus delivered to the Underwriters for use in connection with this offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the
extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The documents incorporated or deemed to be
incorporated by reference in the Registration Statement, any preliminary prospectus and the Prospectus at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the
1934 Act and the rules and regulations of the Commission under the 1934 Act Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Accurate Disclosure</U>.
Neither the Registration Statement nor any amendment thereto, at its effective time, on the date hereof, at the Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or
will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. At the Applicable Time and any Date of Delivery, none of (A)&nbsp;the General Disclosure Package, (B)&nbsp;any individual
Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure Package and (C)&nbsp;any individual Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication, when considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto, as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at
the Closing Time or at any Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration Statement
became effective or when such documents incorporated by reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement, the General Disclosure Package or the Prospectus, as
the case may be, did not and will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration
Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) made in reliance upon and in conformity with written information furnished to the Company by any Underwriter through BofA
expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information in the first paragraph under the heading &#147;Underwriting&#151;Commissions and Discounts,&#148; the information in the second,
third and fourth paragraphs under the heading &#147;Underwriting&#151;Price Stabilization, Short Positions and Penalty Bids&#148; and the information under the heading &#147;Underwriting&#151;Electronic Offer, Sale and Distribution of Shares&#148;
in each case contained in the Prospectus (collectively, the &#147;Underwriter Information&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Issuer Free
Writing Prospectuses</U>. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or
other prospectus deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus made in reliance upon and in conformity with the
Underwriter Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)
<U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials</U>. The Company (A)&nbsp;has not engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication other than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the
consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under the 1933 Act or institutions that are accredited investors within the meaning of Rule 501 under the 1933 Act and (B)&nbsp;has
not authorized anyone other than the Representatives to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company reconfirms that the Representatives have been authorized
to act on its behalf in undertaking <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications specifically authorized by the Company. The Company has not distributed any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than those listed on <U>Schedule <FONT STYLE="white-space:nowrap">B-3</FONT></U> hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Company Not Ineligible Issuer</U>. At the time of filing the Registration Statement and any post-effective amendment
thereto, at the earliest time thereafter that the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not
and is not an &#147;ineligible issuer,&#148; as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Emerging Growth Company Status</U>. From the time of the initial confidential submission of the Registration Statement
to the Commission (or, if earlier, the first date on which the Company engaged directly or through any Person authorized to act on its behalf in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication) through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the 1933 Act (an &#147;Emerging Growth Company&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <U>Independent Accountants</U>. The accountants who certified the financial statements included in the Registration
Statement, the General Disclosure Package and the Prospectus are independent public accountants with respect to the Company as required by the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934 Act Regulations and the Public Company
Accounting Oversight Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <U>Financial Statements</U>. The financial statements included or incorporated by
reference in the Registration Statement, the General Disclosure Package and the Prospectus, together with the related notes, present fairly in all material respects the financial position of the Company and its consolidated subsidiaries at the dates
indicated and the statements of operations and comprehensive loss, stockholders&#146; equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have been prepared in conformity with
U.S. generally accepted accounting principles (&#147;GAAP&#148;) applied on a consistent basis throughout the periods involved except, in the case of unaudited interim financial statements, subject to normal
<FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments and the exclusion of certain footnotes as permitted by the applicable rules of the Commission. The selected financial data and the summary financial information included in the
Registration Statement, the General Disclosure Package and the Prospectus present fairly in all material respects the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included
therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus
under the 1933 Act or the 1933 Act Regulations. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the
information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) <U>No Material Adverse Change in Business</U>. Except as otherwise
stated therein, since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A)&nbsp;there has been no material adverse change in the condition, financial or otherwise,
or in the earnings, business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a &#147;Material Adverse Effect&#148;), (B)&nbsp;there have been
no transactions entered into by the Company or any of its subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its subsidiaries considered as one enterprise, and (C)&nbsp;there has
been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)
<U>Good Standing of the Company</U>. The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties
and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation
to transact business and is in good standing in each other jurisdiction (or such equivalent concept to the extent it exists under the laws of such jurisdiction) in which such qualification is required, whether by reason of the ownership or leasing
of property or the conduct of business, except where the failure so to qualify or to be in good standing would not result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) <U>Good Standing of Subsidiaries</U>. Each &#147;significant subsidiary&#148; of the Company (as such term is defined in
Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> (each, a &#147;Subsidiary&#148; and, collectively, the &#147;Subsidiaries&#148;) has been duly organized and is validly existing in good
standing under the laws of the jurisdiction of its incorporation or organization (or such equivalent concept to the extent it exists under the laws of such jurisdiction), has corporate or similar power and authority to own, lease and operate its
properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification
is required (or such equivalent concept to the extent it exists under the laws of such jurisdiction), whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good
standing would not result in a Material Adverse Effect. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, all of the issued and outstanding capital stock of each Subsidiary has been duly
authorized and validly issued, is fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (or such equivalent concept to the extent it exists under the laws of such jurisdiction) and is owned by the Company, directly or through
subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary were issued in violation of the preemptive or similar rights of any
securityholder of such Subsidiary. The only subsidiaries of the Company are (A)&nbsp;the subsidiaries listed on Exhibit 21 to the Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) <U>Capitalization</U>. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in
the Registration Statement, the General Disclosure Package and the Prospectus in the column entitled &#147;Actual&#148; under the caption &#147;Capitalization&#148; (except for subsequent issuances, if any, pursuant to this Agreement, pursuant to
reservations, agreements or employee benefit or equity incentive plans referred to in the Registration Statement, the General Disclosure Package and the Prospectus, pursuant to the exercise of convertible securities or options
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
referred to in the Registration Statement, the General Disclosure Package and the Prospectus). The outstanding shares of capital stock of the Company have been duly authorized and validly issued
and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> None of the outstanding shares of capital stock of the Company were issued in violation of the preemptive or other similar rights of any securityholder of the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) <U>Authorization of Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) <U>Authorization and Description of Securities</U>. The Shares to be purchased by the Underwriters from the Company
have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth herein, will be validly issued and
fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> and the issuance of the Shares is not subject to the preemptive or other similar rights of any securityholder of the Company except as have been duly and validly waived in
writing as of the date of this Agreement. The Common Stock conforms in all material respects to all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such description conforms
in all material respects to the rights set forth in the instruments defining the same. The Warrants to be purchased by the Underwriters from the Company have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement
and, when executed and delivered by the Company pursuant to this Agreement against payment of the consideration set forth herein, will be valid and binding agreements of the Company, enforceable against the Company in accordance with their terms,
except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles. The Warrant Shares have
been duly authorized and validly reserved for issuance upon exercise of the Warrants in a number sufficient to meet the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the Warrants and in accordance
therewith, will be validly issued, fully paid and nonassessable, and the issuance of the Warrant Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribed for or purchase the Warrant Shares. The
Securities, when issued, will conform to the description thereof set forth in or incorporated into the Registration Statement, the General Disclosure Package and the Prospectus. No holder of Securities will be subject to personal liability by reason
of being such a holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) <U>Registration Rights</U>. There are no persons with registration rights or other similar
rights to have any securities registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other than those rights that have been disclosed in the
Registration Statement, the General Disclosure Package and the Prospectus and have been waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) <U>Absence of
Violations, Defaults and Conflicts</U>. Neither the Company nor any of its subsidiaries is (A)&nbsp;in violation of its charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational document, (B)&nbsp;in default in the
performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of its
subsidiaries is a party or by which it or any of them may be bound or to which any of the properties or assets of the Company or any subsidiary is subject (collectively, &#147;Agreements and Instruments&#148;), except for such defaults that would
not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect, or (C)&nbsp;in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory
body, administrative agency or other authority, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
body or agency having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations (each, a &#147;Governmental Entity&#148;), except for
such violations that would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and performance of this Agreement and the Warrants and the consummation of the transactions
contemplated herein and in the Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities and the Warrant Shares and the use of the proceeds from the sale of the Securities as
described therein under the caption &#147;Use of Proceeds&#148;) and compliance by the Company with its obligations hereunder and under the Warrants have been duly authorized by all necessary corporate action and do not and will not, whether with or
without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties
or assets of the Company or any subsidiary pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in a
Material Adverse Effect), nor will such action result in any violation of (x)&nbsp;the provisions of the charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational document of the Company or any of its subsidiaries or
(y)&nbsp;any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity, except with respect to clause (y), such violations as would not reasonably be expected to, singly or in the aggregate, result in a Material
Adverse Effect. As used herein, a &#147;Repayment Event&#148; means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the
repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) <U>Absence of Labor Dispute</U>. No labor dispute with the employees of the Company or any of its subsidiaries exists
or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any subsidiary&#146;s principal suppliers, manufacturers, partners, collaborators,
customers or contractors, which, in either case, would result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii) <U>Absence of
Proceedings</U>. There is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries,
which would reasonably be expected to result in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in this
Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective properties or
assets is the subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, would not reasonably be expected to result in a
Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix) <U>Accuracy of Exhibits</U>. There are no contracts or documents which are required under
the 1933 Act or the 1933 Act Regulations to be described in the Registration Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <U>Absence of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order,
registration, qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering, issuance or sale of the Securities hereunder or the
consummation of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the transactions contemplated by this Agreement and the Warrants, except (A)&nbsp;such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules
of The Nasdaq Global Market, state securities laws or the rules of the Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;); or (B)&nbsp;such as which the failure to obtain would not, singly or in the aggregate, impair the power or
ability of the Company to perform its obligations under this Agreement or consummate the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxi) <U>Possession of Licenses and Permits</U>. The Company and its subsidiaries possess such permits, licenses, approvals,
consents, exemptions and other authorizations (collectively, &#147;Governmental Licenses&#148;) issued by the appropriate Governmental Entities necessary to conduct the business now operated by them, except where the failure so to possess would not,
singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The Company and its subsidiaries are in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not
reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. The Company has fulfilled and performed all of its material obligations with respect to the Governmental Licenses and no event has occurred which allows, or
after notice or lapse of time would allow, revocation or termination thereof or results in any other material impairment of the rights of the Company as a holder of any permit, except where the failure to so fulfill or perform, or the occurrence of
such event, would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such
Governmental Licenses to be in full force and effect would not, singly or in the aggregate, reasonably be expected to, result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of proceedings
relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would
reasonably be expected to result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxii) <U>Title to Property</U>. The Company and its
subsidiaries have good and marketable title to all real property owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or
encumbrances of any kind except such as (A)&nbsp;are described in the Registration Statement, the General Disclosure Package and the Prospectus or (B)&nbsp;do not, singly or in the aggregate, materially and adversely affect the value of such
property and do not materially interfere with the use made and proposed to be made of such property by the Company or any of its subsidiaries; and all of the leases and subleases material to the business of the Company and its subsidiaries,
considered as one enterprise, and under which the Company or any of its subsidiaries holds properties described in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and effect, except to the extent that
any such failure to be in full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect, and neither the Company nor any such subsidiary has any notice of any material claim of any sort that has been asserted by
anyone adverse to the rights of the Company or any subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such subsidiary to the continued possession of the leased or subleased
premises under any such lease or sublease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiii) <U>Possession of Intellectual Property</U>. The Company and its
subsidiaries own, or have obtained adequate rights and licenses under, or can acquire rights on reasonable terms to, all patents, patent rights, patent applications, inventions, copyrights, other works of authorship, know how (including trade
secrets and other proprietary or confidential information, systems or procedures), trademarks, service marks, trade names, trade and service mark registrations, trade names, designs, processes, licenses, computer programs, technical data and
information, and other intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
property (collectively, &#147;Intellectual Property&#148;) that are necessary to carry on the business of the Company as currently conducted and to commercialize the products or services as
disclosed in the Registration Statement, the General Disclosure Package and the Prospectus as under development (all such Intellectual Property is collectively referred to as the &#147; Company Intellectual Property&#148;). Except as disclosed in
the Registration Statement, the General Disclosure Package and the Prospectus: (A)&nbsp;to the Company&#146;s knowledge there are no third parties who have rights to any Intellectual Property, including no liens, security interest, or other
encumbrances, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the General Disclosure Package and the Prospectus as licensed to the Company or
one or more of its subsidiaries; (B)&nbsp;the Company has taken reasonable steps to secure its interests in the Intellectual Property owned by the Company from its employees and contractors; (C)&nbsp;to the Company&#146;s knowledge, there is no
infringement, misappropriation or violation by third parties of any Company Intellectual Property owned by, or exclusively licensed to, the Company or its subsidiaries; (D)&nbsp;to the Company&#146;s knowledge, the Company is not infringing the
intellectual property rights of third parties and (E)&nbsp;none of the Company Intellectual Property owned by the Company or, to the Company&#146;s knowledge, exclusively licensed to the Company has been adjudged invalid or unenforceable in whole or
in part, in the case of clause (C)&nbsp;and clause (D), which infringement, misappropriation or violation, singly or in the aggregate, would reasonably be expected to result in a Material Adverse Effect. There is no pending or threatened action,
suit, proceeding or claim by others of which the Company has received written notice: (A)&nbsp;challenging the Company&#146;s rights in or to any Company Intellectual Property, and the Company is unaware of any facts which would form a reasonable
basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Company Intellectual Property owned by, or exclusively licensed to, the Company or its subsidiaries, and the Company is unaware
of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product
or service described in the Registration Statement, the General Disclosure Package or the Prospectus as under development, infringe or violate, any Intellectual Property rights of others, and the Company and its subsidiaries are unaware of any facts
which would form a reasonable basis for any such action, suit, proceeding or claim. To the Company&#146;s knowledge, no employee of the Company who has developed Company Intellectual Property is in violation of any term of any employment contract,
patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant
to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company. The Company and its subsidiaries are in compliance in all material respects with the terms of each agreement pursuant to
which Company Intellectual Property is licensed to the Company or any subsidiary, and all such agreements are in full force and effect in accordance with their terms. The patents included in the Company Intellectual Property owned by the Company or,
to the Company&#146;s knowledge, exclusively licensed to the Company are subsisting and have not lapsed and the patent applications in the Intellectual Property owned by the Company or exclusively licensed to the Company are pending and have not
been abandoned. To the Company&#146;s knowledge, except as set forth in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its subsidiary are not obligated or under any liability whatsoever to make any
material payment by way of royalties, fees or otherwise to any owner or licensee of, or other claimant to, any Intellectual Property, with respect to the use thereof or in connection with the conduct of their respective businesses or otherwise. No
technology employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiaries in violation of any contractual or legal obligation binding on the Company, its subsidiaries, or any of their officers,
directors, employees, or contractors, or in violation of any contractual rights of any persons. All patents and patent applications included in the Company Intellectual Property that are owned by or exclusively
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
licensed to the Company have been duly and properly filed and maintained and the parties prosecuting such applications have complied in all material respects with their duty of candor and
disclosure to the U.S. Patent and Trademark Office (the &#147;USPTO&#148;) in connection with such applications. To the Company&#146;s knowledge, there is no patent or published patent application, in the U.S. or other jurisdiction, that is not
included in the Company Intellectual Property and that, in the case of a patent, contains claims, or in the case of a published patent application contains patentable claims, that dominates any of the Company Intellectual Property described in the
Preliminary Prospectus and Prospectus as being owned by or licensed to the Company or that interferes with the issued or pending claims of any of the Company Intellectual Property owned by or, to the Company&#146;s knowledge, exclusively licensed to
the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiv) <U>Clinical Data and Regulatory Compliance</U>. The preclinical tests and clinical trials, and other
studies conducted by or on behalf of the Company (collectively, &#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement, the General Disclosure Package or the Prospectus were and, if still
pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with Good Clinical Practices and all applicable laws, including, without limitation, the
Federal Food, Drug, and Cosmetic Act and its implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, and 312; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived
from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the
General Disclosure Package or the Prospectus; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that
are described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxv)
<U>Compliance with Healthcare Laws</U>. The Company: (i)&nbsp;has operated and currently operates its business in compliance in all material respects with applicable provisions of the health care laws, including Title XVIII of the Social Security
Act, 42 U.S.C. &#167;&#167; 1395-1395lll (the Medicare statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1396-1396w-6</FONT> (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C.
&#167; <FONT STYLE="white-space:nowrap">1320a-7b(b);</FONT> the civil False Claims Act, 31 U.S.C. &#167;&#167; 3729 et seq.; the criminal False Claims Act 42 U.S.C. <FONT STYLE="white-space:nowrap">1320a-7b(a);</FONT> the criminal laws relating to
health care fraud and abuse, including 18 U.S.C. &#167;&#167; 286 and 287 and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; 1320d et seq., (&#147;HIPAA&#148;);
the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1320a-7a;</FONT> the Physician Payments Sunshine Act, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h;</FONT> the exclusion law, 42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7;</FONT> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. &#167;&#167; 17921 et seq.; the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et
seq.; the Public Health Service Act, 42 U.S.C. &#167;&#167; 201 et seq.; the regulations promulgated pursuant to such laws; and any similar federal, state, local and foreign laws and regulations of any governmental authority including the United
States Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review
Board (collectively, the &#147;Regulatory Agencies&#148;) applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of any of the Company&#146;s product candidates,
(collectively the &#147;Health Care Laws&#148;); (ii) has not received any United States Food and Drug Administration Form 483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from any
court or arbitrator or governmental or regulatory authority alleging or asserting <FONT STYLE="white-space:nowrap">non-compliance</FONT> with (A)&nbsp;any Health Care Laws or (B)&nbsp;any licenses, approvals, clearances, exemptions, permits,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
registrations, authorizations, and supplements or amendments thereto required by any such Health Care Laws (&#147;Regulatory Authorizations&#148;); (iii) possesses all Regulatory Authorizations
required to conduct its business as currently conducted and such Regulatory Authorizations are valid and in full force and effect and the Company is not in violation, in any material respect, of any term of any such Regulatory Authorizations;
(iv)&nbsp;has fulfilled and performed all of its material obligations with respect to the Regulatory Authorizations and, to the Company&#146;s knowledge, no event has occurred which allows, or after notice or lapse of time would allow, revocation or
termination thereof or results in any other material impairment of the rights of the holder of any such Regulatory Authorization; (v)&nbsp;has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action (&#147;Proceeding&#148;) from any governmental authority including any Regulatory Agency or any other third party alleging a material violation of any Health Care Laws or Regulatory Authorizations or limiting, suspending,
modifying, or revoking any material Regulatory Authorizations, and has no knowledge that any governmental authority including any Regulatory Agencies or any other third party is considering any Proceeding; (vi)&nbsp;has filed, obtained, maintained
or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations (&#147;Reports&#148;) and that all such Reports
were materially complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission); (vii) along with its employees, officers and directors, and to the Company&#146;s knowledge, independent contractors
and agents, is not a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar
agreements with or imposed by any governmental authority including any Regulatory Agencies; and (viii)&nbsp;along with its employees, officers and directors, and, to the Company&#146;s knowledge, independent contractors and agents, has not been
excluded, suspended or debarred from, or otherwise ineligible for participation in any government health care program or human clinical research. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvi) <U>Environmental Laws</U>. Except as would not, singly or in the aggregate, result in a Material Adverse Effect,
(A)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof,
including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface
strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products,
asbestos-containing materials or mold (collectively, &#147;Hazardous Materials&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;Environmental
Laws&#148;), (B) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (C)&nbsp;there are no pending or, to the
Company&#146;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigations or proceedings relating to any Environmental Law against the
Company or any of its subsidiaries and (D)&nbsp;to the Company&#146;s knowledge, there are no events or circumstances that would reasonably be expected to form the basis of an order for <FONT STYLE="white-space:nowrap">clean-up</FONT> or
remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvii) <U>Accounting Controls and Disclosure Controls</U>. The Company and
its subsidiaries, on a consolidated basis, maintain a system of effective internal control over financial reporting (as defined under Rules <FONT STYLE="white-space:nowrap">13-a15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the
1934 Act Regulations) and a system of internal accounting controls sufficient to provide reasonable assurances that (A)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (B)&nbsp;transactions are
recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific
authorization; (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (E)&nbsp;the interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, since the end of the Company&#146;s most recent audited fiscal year, there has been
(1)&nbsp;no material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and (2)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially and adversely
affected, or is reasonably likely to materially and adversely affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and each of its subsidiaries maintain an effective system of disclosure controls and procedures (as defined in Rule
<FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the 1934 Act Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports that it files
or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#146;s rules and forms, and is accumulated and communicated to the Company&#146;s management, including its principal
executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions regarding disclosure </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxviii) <U>Compliance with the Sarbanes-Oxley Act</U>. There is and has been no failure on the part of the Company or any of
the Company&#146;s directors or officers, in their capacities as such, to comply in all material respects with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (the
&#147;Sarbanes-Oxley Act&#148;), including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxix) <U>Payment of Taxes</U>. All United States federal income tax returns of the Company and its subsidiaries required by
law to be filed by them have been filed or a timely extension has been requested thereof and all taxes shown by such returns, which are due and payable, have been paid, except taxes against which appeals have been or will be promptly taken and as to
which adequate reserves have been provided in accordance with GAAP or to the extent any failure to file or pay such taxes or assessments would not result in a Material Adverse Effect. The United States federal income tax returns of the Company
through the fiscal year ended December&nbsp;31, 2018 have been settled and no assessment in connection therewith has been made against the Company. The Company and its subsidiaries have filed all other tax returns that are required to have been
filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to do so would not reasonably be expected to result in a Material Adverse Effect, and has paid all taxes due pursuant to such returns or pursuant
to any assessment received by the Company and its subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by the Company in accordance with GAAP or where the failure
to do so would not result in a Material Adverse Effect. No tax deficiency has been determined adversely to the Company (nor does the Company have any notice or knowledge of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
tax deficiency which could reasonably be expected to be determined adversely to the Company). The charges, accruals and reserves on the books of the Company in respect of any income or
corporation tax liability for any years not finally determined are adequate to meet any assessments or <FONT STYLE="white-space:nowrap">re-assessments</FONT> for additional income tax for any years not finally determined, except to the extent of any
inadequacy that would not reasonably be expected to result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxx) <U>Insurance</U>. The
Company and its subsidiaries carry or are entitled to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering such risks as the Company reasonably believes is generally maintained by companies of
established repute and comparable size engaged in the same or similar business, and all such insurance is in full force and effect. The Company has no reason to believe that it or any of its subsidiaries will not be able (A)&nbsp;to renew its
existing insurance coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be
expected to result in a Material Adverse Effect. Neither of the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxi) <U>Investment Company Act</U>. The Company is not required, and upon the issuance and sale of the Securities and Warrant
Shares as herein contemplated and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be required, to register as an &#147;investment company&#148;
under the Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxii) <U>Absence of Manipulation</U>. Neither the Company nor any
affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action which is designed, or would reasonably be expected, to cause or result in, or which constitutes, the stabilization or manipulation of
the price of any security of the Company to facilitate the sale or resale of the Securities and Warrant Shares or to result in a violation of Regulation M under the 1934 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiii) <U>Foreign Corrupt Practices Act</U>. None of the Company, any of its subsidiaries or, to the knowledge of the
Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of
the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#147;FCPA&#148;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in
furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#147;foreign official&#148; (as such term is defined
in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in
compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiv) <U>Money Laundering Laws</U>. The operations of the Company and its subsidiaries are and have been conducted at all
times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
enforced by any Governmental Entity (collectively, the &#147;Money Laundering Laws&#148;); and no action, suit or proceeding by or before any Governmental Entity involving the Company or any of
its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxv) <U>OFAC</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer,
agent, employee, affiliate or representative of the Company or any of its subsidiaries is an individual or entity (&#147;Person&#148;), currently the subject or target of any sanctions administered or enforced by the United States Government,
including, without limitation, the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control (&#147;OFAC&#148;), the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions
authority (collectively, &#147;Sanctions&#148;), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the
Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such
funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvi) <U>Lending Relationship</U><I>. </I>Except as disclosed in the Registration Statement, the General Disclosure Package
and the Prospectus, the Company (i)&nbsp;does not have any&nbsp;material lending or other relationship with any banking or lending affiliate of any Underwriter and (ii)&nbsp;does not intend to use any of the proceeds from the sale of the Securities
to repay any outstanding debt owed to any affiliate of any Underwriter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvii) <U>Statistical and Market-Related
Data</U>. Any statistical and market-related data included in the Registration Statement, the General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and
accurate and, to the extent required, the Company has obtained the written consent to the use of such data from such sources. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxviii) <U>No Rated Debt</U>. No securities issued or guaranteed by, or loans to, the Company are rated by any
&#147;nationally recognized statistical rating organization&#148; (as defined by the Commission in Section&nbsp;3(a)(62) of the 1934 Act). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxix) <U>Data Privacy and Security Laws</U>. The Company and its subsidiaries are, and at all prior times since inception
were, in material compliance with all applicable data privacy and data security laws and regulations, including without limitation HIPAA, the HITECH Act, the European Union General Data Protection Regulation (&#147;GDPR&#148;) (EU 2016/679), and the
California Consumer Privacy Act (&#147;CCPA&#148;) (and all other applicable laws and regulations with respect to Personal Data (defined below) that have been announced as of the date hereof as becoming effective within 12 months after the date
hereof, and for which any <FONT STYLE="white-space:nowrap">non-compliance</FONT> with same would be reasonably likely to create a material liability) (collectively, the &#147;Privacy Laws&#148;). To support compliance with the Privacy Laws, the
Company and its subsidiaries have in place, and take appropriate steps reasonably designed to ensure compliance in all material respects with, policies and procedures relating to data privacy and data security and the collection, storage, use,
disclosure, handling, and analysis of Sensitive Data (the &#147;Policies&#148;). At all times since inception, the Company has provided accurate notice of its Policies then in effect to its customers, employees, third party vendors and
representatives. Each of the Company Policies provides accurate and sufficient notice of the Company&#146;s then-current privacy practices relating to its subject matter and such Company Policies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
do not contain any material omissions of the Company&#146;s then-current privacy practices. &#147;Personal Data&#148; means (i)&nbsp;a natural person&#146;s name, street address, telephone
number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank information, or customer or account number;
(ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii)&nbsp;Protected Health Information as defined by HIPAA; (iv) &#147;personal data&#148; as
defined by GDPR, and (v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#146;s health or sexual
orientation that is not aggregated with the data of other individuals or otherwise irreversibly anonymized such that a natural person cannot be identified. &#147;Sensitive Data&#148; means any Personal Data or any sensitive, proprietary, or trade
secret information of the Company or any such information of a third party in the possession of the Company. The Company and its subsidiaries since inception have at all times made all disclosures to users or customers required by applicable laws
and regulatory rules or requirements, and have provided accurate notice of its Policies then in effect to its customers, employees, third party vendors and representatives. None of such disclosures made or contained in any of the Policies have been
inaccurate, misleading, deceptive or in violation of any Privacy Laws or Policies in any material respect. The execution, delivery and performance of this Agreement or any other agreement referred to in this Agreement will not result in a breach of
violation of any Privacy Laws or Policies. The Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the
Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective
action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xl) <U>Cybersecurity; Data Protection</U>. (A)&nbsp;To the Company&#146;s knowledge, and except as has been disclosed in the
Registration Statement, the General Disclosure Package and the Prospectus, there has been no security breach or incident, attack, or other compromise of or relating to any of the Company or its subsidiaries information technology and computer
systems, networks, hardware, software, data and databases (including the data of their respective customers, employees, suppliers, vendors and any third party data maintained, processed or stored by the Company and its subsidiaries, and any such
data processed or stored by third parties on behalf of the Company and its subsidiaries), equipment or technology (collectively, &#147;IT Systems and Data&#148;): (B) neither the Company nor its subsidiaries have been notified of, and each of them
have no knowledge of any event or condition that would reasonably be expected to result in, any material security breach or incident, attack or other compromise to their IT Systems and Data and (C)&nbsp;the Company and its subsidiaries have
implemented appropriate controls, policies, procedures, and technological safeguards reasonably likely to maintain and protect the integrity, continuous operation, redundancy and security of their IT Systems and Data reasonably consistent with
industry standards and practices, or as required by applicable regulatory standards. The Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or
arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access,
misappropriation or modification, except as would not be reasonably expected to result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Officer</I><I>&#146;</I><I>s Certificates</I>. Any certificate signed by any officer of the Company or any of its subsidiaries delivered to the Representatives or to counsel for the Underwriters shall be deemed a representation and warranty by
the Company to each Underwriter as to the matters covered thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Sale and Delivery to Underwriters; Closing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Securities</I>. On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set
forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company, (i)&nbsp;at the combined price per Share and accompanying Common Warrant set
forth in <U>Schedule A</U> (the &#147;Share Purchase Price&#148;), the number of Shares and accompanying Common Warrants set forth in <U>Schedule A</U> opposite the name of such Underwriter, and (ii)&nbsp;at the combined price per <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and accompanying Common Warrant set forth in <U>Schedule A</U>, the number of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and accompanying Common Warrants set forth in <U>Schedule
A</U> opposite the name of such Underwriter, plus any additional number of Securities which such Underwriter may become obligated to purchase pursuant to the provisions of Section&nbsp;10 hereof, subject, in each case, to such adjustments among the
Underwriters as Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Payment</I>. Payment of the purchase price for, and delivery of certificates or security entitlements for, the Shares and Warrants shall be made at the offices of Cooley LLP, 3 Embarcadero Center, 20th Floor, San Francisco, California 94111, or
at such other place as shall be agreed upon by the Representatives and the Company, at 10:00&nbsp;a.m. (New York City time) on the second (third, if the pricing occurs after 4:30 p.m. (New York City time) on any given day) business day after the
date hereof (unless postponed in accordance with the provisions of Section&nbsp;10), or such other time not later than ten business days after such date as shall be agreed upon by the Representatives and the Company (such time and date of payment
and delivery being herein called &#147;Closing Time&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment shall be made to the Company by wire transfer of immediately
available funds to the bank accounts designated by the Company against delivery to the Representatives for the respective accounts of the Underwriters of certificates or security entitlements for the Securities to be purchased by them. It is
understood that each Underwriter has authorized the Representatives, for its account, to accept delivery of, receipt for, and make payment of the purchase price for, the Securities which it has agreed to purchase. Each of the Representatives,
individually and not as representative of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Securities to be purchased by any Underwriter whose funds have not been received by the Closing Time or the
relevant Date of Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Company and the Representatives shall instruct purchasers of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and accompanying Common Warrants in the public offering to make payment for the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and accompanying Common Warrants on the Closing
Date to the Company by wire transfer in immediately available funds to the account specified by the Company, at a purchase price of $3.549 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and accompanying Common Warrant, in lieu of
payment by the Underwriters for such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and accompanying Common Warrants, and the Company shall deliver such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and accompanying Common
Warrants to such purchasers on the Closing Date in definitive form against such payment, in lieu of the Company&#146;s obligation to deliver such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and accompanying Common Warrants to the
Underwriters; provided that, the Company shall promptly (but in no event later than the Closing Date), pay $0.213 per such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and accompanying Common Warrant to the Underwriters by wire
transfer in immediately available funds to the account specified by the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any purchaser of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in the public offering fails to make payment to the Company for all or part of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants on the Closing Date, the Representatives may elect,
by written notice to the Company, to receive shares of Common Stock and accompanying Common Warrants at the Share Purchase Price in lieu of all or a portion of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to be delivered to the
Underwriters under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Covenants</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Covenants of the Company</I>. The Company covenants with each Underwriter as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Compliance with Securities Regulations and Commission Requests</I>. The Company will comply with the requirements of
Rule 430B, and will notify the Representatives promptly, and confirm the notice in writing, (i)&nbsp;when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have
been filed, (ii)&nbsp;of the receipt of any comments from the Commission, (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus, including any document
incorporated by reference therein, or for additional information, (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or
suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes
or of any examination pursuant to Section&nbsp;8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v)&nbsp;if the Company becomes the subject of a proceeding under Section&nbsp;8A of the 1933 Act in connection with the offering
of the Securities. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain
promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will make every reasonable effort to
prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof as soon as reasonably practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Continued Compliance with Securities Laws</I>. The Company will comply with the 1933 Act, the 1933 Act Regulations, the
1934 Act and the 1934 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a
prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (&#147;Rule 172&#148;), would be) required by the 1933 Act to be delivered in connection with sales of the Securities, any event
shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend the Registration Statement in order that the Registration Statement will not include an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;amend or supplement the General Disclosure Package or the Prospectus in order
that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the
circumstances existing at the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of
the 1933 Act or the 1933 Act Regulations, the Company will promptly (A)&nbsp;give the Representatives notice of such event, (B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the
Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any such amendment or supplement
and (C)&nbsp;file with the Commission any such amendment or supplement; provided, that the Company shall not file or use any such amendment or supplement to which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Representatives or counsel for the Underwriters shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may
reasonably request. The Company has given the Representatives notice of any filings made pursuant to the 1934 Act or 1934 Act Regulations as soon as practicable prior to the Applicable Time; the Company will give the Representatives notice of its
intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representatives with copies of any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or
use any such document to which the Representatives or counsel for the Underwriters shall reasonably object. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)
<I>Delivery of Registration Statements</I>. The Company has furnished or will deliver to the Representatives and counsel for the Underwriters, without charge, conformed copies of the Registration Statement as originally filed and each amendment
thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed to be incorporated by reference therein) and conformed copies of all consents and certificates of experts. The copies of the
Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Delivery of Prospectuses</I>. The Company has delivered to each
Underwriter, without charge, as many copies of each preliminary prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The Company will furnish to each
Underwriter, without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the Prospectus (as
amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission
pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Blue
Sky Qualifications</I>. The Company will use its reasonable best efforts, in cooperation with the Underwriters, to qualify the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or
foreign) as the Representatives may designate and to maintain such qualifications in effect so long as required to complete the distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to
service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise
so subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <I>Rule 158</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in
order to make generally available (which may be satisfied by filing with the Commission pursuant to EDGAR) to its securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters the benefits
contemplated by, the last paragraph of Section&nbsp;11(a) of the 1933 Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <I>Use of Proceeds</I>. The Company will
use the net proceeds received by it from the sale of the Securities in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under &#147;Use of Proceeds.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <I>Listing</I>. The Company will use its reasonable best efforts to
effect and maintain the listing of the Common Stock (including the Shares and Warrant Shares) on The Nasdaq Global Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) <I>Restriction on Sale of Securities</I>. During a period of 60 days from the date of the Prospectus, the Company will
not, without the prior written consent of the Representatives, (i)&nbsp;directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file or confidentially submit any registration statement under the 1933 Act with
respect to any of the foregoing or (ii)&nbsp;enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap
or transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise. The foregoing sentence shall not apply to (A)&nbsp;the Securities to be sold hereunder (including the
issuance of the Warrants and Warrant Shares), (B) any shares of Common Stock issued by the Company upon the exercise (including any net exercise or exercise by delivery of already-owned shares of Common Stock) of an option or warrant or the
conversion of a security outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (C)&nbsp;any shares of Common Stock issued or options to purchase Common Stock or restricted
stock units covering shares of Common Stock granted pursuant to existing employee benefit plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (D)&nbsp;any shares of Common Stock issued
or options to purchase shares of Common Stock granted pursuant to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure
Package and the Prospectus, (E)&nbsp;the filing by the Company of a registration statement with the Commission on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto with respect to the registration of securities to be
offered under any plans or programs referred to in clauses (C)&nbsp;and (D) above and (F)&nbsp;the sale or issuance of or entry into an agreement to sell or issue shares of Common Stock or other securities issued in connection with any
(1)&nbsp;merger, (2) acquisition of securities, businesses, properties or other assets, (3)&nbsp;joint venture or (4)&nbsp;strategic alliance or relationship; provided, that the aggregate number of shares issued pursuant to this clause
(F)&nbsp;shall not exceed 10.0% of the total number of outstanding shares of Common Stock immediately following the issuance and sale of the Securities; provided further that the recipient of any such shares of Common Stock or securities issued
pursuant to clauses (B), (C), (D) and (F)&nbsp;during the <FONT STYLE="white-space:nowrap">60-day</FONT> restricted period shall enter into an agreement substantially in the form of <U>Exhibit A</U> hereto with respect to (and not in excess of) the <FONT
STYLE="white-space:nowrap">60-day</FONT> restricted period and only if such recipient did not previously enter into such an agreement with the Representatives. Notwithstanding the foregoing, the Company may effect sales pursuant to the Sales
Agreement, by and among the Company, SVB Securities and Cantor Fitzgerald&nbsp;&amp; Co, dated March&nbsp;25, 2021, provided that (i)&nbsp;the Company notifies the Representatives prior to effecting any sales and (ii)&nbsp;no sales shall be made for
a period of 30 days from the date of the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Reporting Requirements</I>. The Company, during the period
when a Prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934 Act within
the time periods required by the 1934 Act and 1934 Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the 1933 Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) <I>Issuer Free Writing Prospectuses</I>. The Company agrees that,
unless it obtains the prior written consent of the Representatives, it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#147;free writing
prospectus,&#148; or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses
listed on <U>Schedule <FONT STYLE="white-space:nowrap">B-2</FONT></U> hereto and any &#147;road show that is a written communication&#148; within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representatives. The Company represents
that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Representatives as an &#147;issuer free writing prospectus,&#148; as defined in Rule 433, and that it has complied and
will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there
occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included
or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the
Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) <I>Certification Regarding Beneficial Owners</I>. The Company will deliver to the Representatives, on the date of
execution of this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company undertakes to provide such additional supporting
documentation as the Representatives may reasonably request in connection with the verification of the foregoing certification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) <I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials</I>. If
at any time following the distribution of any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication there occurred or occurs an event or development as a result of which such Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) <I>Emerging Growth Company Status</I>. The Company will promptly notify the Representatives if the Company ceases to be
an Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of the Securities within the meaning of the 1933 Act and (ii)&nbsp;completion of the <FONT STYLE="white-space:nowrap">60-day</FONT> restricted
period referred to in Section&nbsp;3(a)(ix). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) The Company shall, at all times while any Warrants are outstanding, use
its commercially reasonable best efforts to maintain a registration statement covering the issue and sale of the Warrant Shares upon exercise of the Warrants such that the Warrant Shares, when issued, will not be subject to resale restrictions under
the Securities Act except to the extent that the Warrant Shares are owned by affiliates. The Company shall, at all times while any Warrants are outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise
unreserved shares of Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such Warrants, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding
Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Payment of Expenses</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Expenses</I>. The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement
including (i)&nbsp;the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Underwriters
of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors,
(iii)&nbsp;the preparation, issuance and delivery of the certificates or security entitlements for the Securities to the Underwriters and the Warrants to the purchasers, including any stock or other transfer taxes and any stamp or other duties
payable upon the sale, issuance or delivery of the Securities to the Underwriters, (iv)&nbsp;the fees and disbursements of the Company&#146;s counsel, accountants and other advisors, (v)&nbsp;the qualification of the Securities under securities laws
in accordance with the provisions of Section&nbsp;3(a)(v) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of the Blue Sky Survey
and any supplement thereto, (vi)&nbsp;the fees and expenses of any transfer agent or registrar for the Securities, (vii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in
connection with the marketing of the Securities, including without limitation, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged by the Company or with the Company&#146;s prior
written consent (which may be by email) in connection with the road show presentations, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and the cost of aircraft and other transportation
(provided that the travel and lodging expenses of the Representatives shall be paid for by the Underwriters), and fifty percent (50%) of the cost of any aircraft chartered in connection with the road show (with the Underwriters agreeing to pay for
the other fifty percent (50%) of the cost of such chartered aircraft), (viii) the filing fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of
the Securities, with such legal fees, taken together with the legal fees described in clause (v)&nbsp;above, not to exceed $40,000; (ix) the fees and expenses incurred in connection with the listing of the Shares and Warrant Shares on The Nasdaq
Global Market and (x)&nbsp;the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made
by the Underwriters caused by a breach of the representation contained in the third sentence of Section&nbsp;1(a)(ii). Except as provided in this Section&nbsp;4, the Underwriters will pay all of their own costs and expenses, including the fees and
disbursements of their counsel, stock transfer taxes payable on the resale of any of the Securities by them and any advertising expenses connected with any offers they may make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Termination of Agreement</I>. If this Agreement is terminated by the Representatives in accordance with the provisions of
Section&nbsp;5, Section&nbsp;9(a)(i) or (iii)&nbsp;or Section&nbsp;10 hereof, the Company shall reimburse the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters for all of their reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses actually incurred, including the reasonable fees and disbursements of counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Conditions of Underwriters&#146; Obligations</U>. The obligations of the several Underwriters hereunder are subject to the
accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its
covenants and other obligations hereunder, and to the following further conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Effectiveness of Registration Statement</I>.
The Registration Statement has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or
suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&#146;s knowledge, contemplated; and the Company has complied with
each request (if any) from the Commission for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Opinion and Negative Assurance Letter of Counsel for Company</I>. At the Closing
Time, the Representatives shall have received an opinion and negative assurance letter, dated the Closing Time, of Gibson, Dunn&nbsp;&amp; Crutcher LLP, counsel for the Company, in form and substance satisfactory to counsel for the Underwriters,
together with signed or reproduced copies of such letter for each of the other Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Opinion of Intellectual Property
Counsel for Company</I>. At the Closing Time, the Representatives shall have received the favorable opinion, dated the Closing Time, of Greenberg Traurig, LLP, intellectual property counsel for the Company, in form and substance satisfactory to
counsel for the Underwriters, together with signed or reproduced copies of such letter for each of the other Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Opinion
and Negative Assurance Letter of Counsel for Underwriters</I>. At the Closing Time, the Representatives shall have received the favorable opinion and negative assurance letter, dated the Closing Time, of Cooley LLP, counsel for the Underwriters, in
the form and substance reasonably satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Officers&#146; Certificate</I>. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as
of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any Material Adverse Effect change, and the Representatives shall have received a certificate of the Chief Executive Officer or the
President of the Company and of the chief financial or chief accounting officer of the Company, dated the Closing Time, to the effect that (i)&nbsp;there has been no such material adverse change, (ii)&nbsp;the representations and warranties of the
Company in this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii)&nbsp;the Company has complied in all material respects with all agreements and satisfied all conditions on
its part to be performed or satisfied at or prior to the Closing Time, and (iv)&nbsp;no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any
preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Accountant&#146;s Comfort Letter</I>. At the time of the execution of this Agreement, the Representatives shall have received from KPMG
LLP, a letter, dated such date, in form and substance satisfactory to the Representatives, together with reproduced copies of such letter for each of the other Underwriters containing statements and information of the type ordinarily included in
accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Bring-down Comfort Letter</I>. At the Closing Time, the Representatives shall have received from KPMG LLP, a letter, dated as of the
Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (f)&nbsp;of this Section, except that the specified date referred to shall be a date not more than three business days prior to the
Closing Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Approval of Listing</I>. At the Closing Time, the Shares and Warrant Shares shall have been approved for listing on
The Nasdaq Global Market, subject only to official notice of issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Objection</I>. FINRA has confirmed that it has not raised any objection with
respect to the fairness and reasonableness of the underwriting terms and arrangements relating to the offering of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. At the date of this Agreement, the Representatives shall have received an agreement substantially in the form of Exhibit&nbsp;A hereto signed by each of the Company&#146;s directors and
officers and their respective affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Maintenance of Rating</I>. Neither the Company nor its subsidiaries have any debt
securities or preferred stock that are rated by any &#147;nationally recognized statistical rating agency&#148; (as defined in Section&nbsp;3(a)(62) of the 1934 Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Additional Documents</I>. At the Closing Time and at each Date of Delivery (if any) counsel for the Underwriters shall have been
furnished with such documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the
representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably satisfactory
in form and substance to the Representatives and counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Termination of Agreement</I>. If any condition
specified in this Section shall not have been fulfilled when and as required to be fulfilled, this Agreement may be terminated by the Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the
case may be, and such termination shall be without liability of any party to any other party except as provided in Section&nbsp;4 and except that Sections 1, 6, 7, 8, 14, 15, 16 and 17 shall survive any such termination and remain in full force and
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term
is defined in Rule 501(b) under the 1933 Act (each, an &#147;Affiliate&#148;)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any
untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, or the omission or alleged omission
therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A)&nbsp;in any preliminary
prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, the General Disclosure Package or the Prospectus (or any amendment or
supplement thereto), or (B)&nbsp;in any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (&#147;Marketing Materials&#148;), including any road
show (as defined in Rule 433(h) under the 1933 Act) or investor presentations made to investors by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, Issuer Free Writing Prospectus,
any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, Prospectus or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) against any and all loss, liability, claim, damage and expense
whatsoever, as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such
untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section&nbsp;6(d) below) any such settlement is effected with the written consent of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the
Representatives), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue
statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i)&nbsp;or (ii) above; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package, any preliminary
prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any Marketing Materials or the Prospectus (or any amendment or supplement
thereto) in reliance upon and in conformity with the Underwriter Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of Company and Directors and
Officers</I>. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of
Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a)&nbsp;of this Section, as incurred, but only with respect to
untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package,
any preliminary prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any Marketing Materials or the Prospectus (or any amendment
or supplement thereto) in reliance upon and in conformity with the Underwriter Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Actions against Parties;
Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an
indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on
account of this indemnity agreement. In the case of parties indemnified pursuant to Section&nbsp;6(a) above, counsel to the indemnified parties shall be selected by the Representatives, and, in the case of parties indemnified pursuant to
Section&nbsp;6(b) above, counsel to the indemnified parties shall be selected by, in the case of any indemnification in favor of the Company or its directors of officers, the Company. An indemnifying party may participate at its own expense in the
defense of any such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event shall the indemnifying parties be liable for
fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction arising
out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section&nbsp;6 or Section&nbsp;7 hereof (whether or not the indemnified parties
are actual or potential parties thereto), unless such settlement, compromise or consent (i)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and
(ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Settlement without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall have requested an indemnifying party
to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section&nbsp;6(a)(ii) or settlement of any claim in connection with any
violation referred to in Section&nbsp;6(d) effected without its written consent if (i)&nbsp;such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall
have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the
date of such settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Contribution</U>. If the indemnification provided for in Section&nbsp;6 hereof is for any reason
unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses,
liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other
hand, from the offering of the Securities pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i)&nbsp;above but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages
or expenses, as well as any other relevant equitable considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative benefits received by the Company, on the one hand, and
the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this
Agreement (after deducting underwriting discounts and commissions but before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth
on the cover of the Prospectus, bear to the aggregate initial public offering price of the Securities as set forth on the cover of the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other
things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree
that it would not be just and equitable if contribution pursuant to this Section&nbsp;7 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not
take account of the equitable considerations referred to above in this Section&nbsp;7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section&nbsp;7 shall be
deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or
threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;7, no Underwriter shall be required to
contribute any amount in excess of the underwriting commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the 1933 Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;7, each person, if any, who
controls an Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act and each Underwriter&#146;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each
director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act shall have the
same rights to contribution as the Company. The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;7 are several in proportion to the number of Securities set forth opposite their respective names in <U>Schedule
A</U> hereto and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Representations, Warranties and Agreements to Survive</U>. All representations, warranties and
agreements contained in this Agreement or in certificates of officers of the Company or any of its subsidiaries or submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i)&nbsp;any investigation made by or on
behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii)&nbsp;delivery of and payment for the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Termination of Agreement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Termination</I>. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing
Time (i)&nbsp;if there has been, in the judgment of the Representatives, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or
the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries considered as one enterprise, whether or not arising in the ordinary
course of business, or (ii)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or
any change or development involving a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representatives, impracticable or
inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii)&nbsp;if trading in any securities of the Company has been suspended or materially limited by the Commission or The Nasdaq
Global Market, or (iv)&nbsp;if trading generally on the NYSE MKT or the New York Stock Exchange or in The Nasdaq Global Market has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for
prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v)&nbsp;a material disruption has occurred in commercial banking or securities settlement or clearance services in the
United States or with respect to Clearstream or Euroclear systems in Europe, or (vi)&nbsp;if a banking moratorium has been declared by either Federal or New York authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Liabilities</I>. If this Agreement is terminated pursuant to this Section, such
termination shall be without liability of any party to any other party except as provided in Section&nbsp;4 hereof, and provided further that Sections 1, 6, 7, 8, 14, 15, 16 and 17 shall survive such termination and remain in full force and effect.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Default by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the Closing Time or a
Date of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the &#147;Defaulted Securities&#148;), the Representatives shall have the right, within 24&nbsp;hours thereafter, to make arrangements for
one or more of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein
set forth; if, however, the Representatives shall not have completed such arrangements within such <FONT STYLE="white-space:nowrap">24-hour</FONT> period, then if the number of Defaulted Securities does not exceed 10% of the number of Securities to
be purchased on such date, each of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting
obligations hereunder bear to the underwriting obligations of all <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No action taken pursuant to this Section shall relieve any defaulting Underwriter from liability in respect of its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any such default which does not result in a termination of this Agreement, either the (i)&nbsp;Representatives or
(ii)&nbsp;the Company shall have the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General
Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term &#147;Underwriter&#148; includes any person substituted for an Underwriter under this Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if
mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to (i)&nbsp;BofA at One Bryant Park, New York, New York 10036, attention of Syndicate Department (facsimile: (646) <FONT
STYLE="white-space:nowrap">855-3073),</FONT> with a copy to ECM Legal (facsimile: (212) <FONT STYLE="white-space:nowrap">230-8730)and</FONT> (ii)&nbsp;SVB Securities at 1301 Avenue of the Americas,
12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, New York 10019, attention of Stuart R. Nayman, Esq. (facsimile (646) <FONT STYLE="white-space:nowrap">499-7051);</FONT> and notices to the Company shall be directed to it at
89bio, Inc., 142 Sansome Street, 2nd Floor, San Francisco, California 94104, attention of Rohan Palekar, Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
12. <U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the Securities pursuant to this Agreement, including the determination of the combined initial public offering price of the
Securities and any related discounts and commissions, is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, and does not
constitute a recommendation, investment advice, or solicitation of any action by the Underwriters, (b)&nbsp;in connection with the offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a
principal and is not the agent or fiduciary of the Company or any of its subsidiaries, or their respective stockholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary
responsibility in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company or any of its subsidiaries on other
matters) and no Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be engaged in a
broad range of transactions that involve interests that differ from those of the Company (e)&nbsp;the Underwriters have not provided any legal, accounting, financial, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory, investment or tax advice with respect to the offering of the Securities and the Company has consulted its own respective legal, accounting, financial, regulatory, investment and tax
advisors to the extent it deemed appropriate and (f)&nbsp;none of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment advice or solicitation of any action by the
Underwriters with respect to any entity or natural person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Recognition of the U.S. Special Resolution Regimes</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the
transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any
such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any
Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;13, a &#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted
in accordance with, 12 U.S.C. &#167; 1841(k). &#147;Covered Entity&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a
&#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b).
<B>&#147;</B>Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#147;U.S. Special Resolution Regime&#148; means each of
(i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Parties</U>. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their
respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Underwriters and the Company and their respective successors and the controlling
persons and officers and directors referred to in Sections&nbsp;6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement
and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal
representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Trial by Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and
affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions
contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>GOVERNING LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO
THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 17. <U>Consent to Jurisdiction</U>. Any legal suit, action or proceeding arising out
of or based upon this Agreement or the transactions contemplated hereby shall be instituted in (i)&nbsp;the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or (ii)&nbsp;the courts of
the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the &#147;Specified Courts&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to
the enforcement of a judgment of any such court, as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by
mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any
suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 18. <U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN,
SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 19. <U>Counterparts and Electronic Signatures</U>. This Agreement may be
executed in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same Agreement. Electronic signatures complying with the New York Electronic Signatures and
Records Act (N.Y. State Tech. &#167;&#167; <FONT STYLE="white-space:nowrap">301-309),</FONT> as amended from time to time, or other applicable law will be deemed original signatures for purposes of this Agreement. Transmission by telecopy,
electronic mail or other transmission method of an executed counterpart of this Agreement will constitute due and sufficient delivery of such counterpart. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 20. <U>Effect of Headings</U>. The section headings herein are for convenience only and shall not affect the construction hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature pages follow] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>89BIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ryan Martins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ryan Martins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Underwriting Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CONFIRMED AND ACCEPTED,</B><BR>&nbsp;&nbsp;&nbsp;&nbsp;as of the date first above written:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BOFA SECURITIES, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SVB SECURITIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>BOFA SECURITIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Aamir Mecklai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Aamir Mecklai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>SVB SECURITIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anurag Jindal</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Anurag Jindal</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Authorized Signatory</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and as Representatives of the other Underwriters named in <U>Schedule A</U> hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Underwriting Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined initial public offering price per Share and accompanying Common Warrant shall be $3.55. The combined initial public offering price per <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and accompanying Common Warrant shall be $3.549. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per Share and accompanying
Common Warrant to be paid by the several Underwriters shall be $3.337, being an amount equal to the applicable combined initial public offering price set forth above less $0.213 per Share and accompanying Common Warrant; and the purchase price per <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and accompanying Common Warrant to be paid by the several Underwriters shall be $3.336, being an amount equal to the applicable combined initial public offering price set forth above less $0.213
per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and accompanying Common Warrant, subject to adjustment in accordance with Section&nbsp;2(b) for dividends or distributions declared by the Company and payable on the Securities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Name of Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>Common<BR>Warrants<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,190,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,058,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,248,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,882,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,502,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,385,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RBC Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,054,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">873,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,928,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,494,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">635,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,129,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raymond James&nbsp;&amp; Associates, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,494,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">635,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,129,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">560,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">798,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,675,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,944,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,619,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Common Warrant is exercisable for 0.5 of a share of Common Stock. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch <FONT
STYLE="white-space:nowrap">A-1</FONT> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE <FONT STYLE="white-space:nowrap">B-1</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pricing Terms </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is selling 18,675,466 Shares and 18,675,466 accompanying Common Warrants to purchase 9,337,733
shares of Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The combined initial public offering price per Share and accompanying Common Warrant shall be $3.55.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is selling 7,944,252 <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase
7,944,252 shares of Common Stock and 7,944,252 accompanying Common Warrants to purchase 3,972,126 shares of Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The combined initial public offering price per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and
accompanying Common Warrant shall be $3.549. </P></TD></TR></TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch <FONT
STYLE="white-space:nowrap">B-1</FONT> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE <FONT STYLE="white-space:nowrap">B-2</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Free Writing Prospectuses </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE <FONT STYLE="white-space:nowrap">B-3</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sch <FONT
STYLE="white-space:nowrap">B-3</FONT> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> from Directors, Officers or other Stockholders </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pursuant to Section&nbsp;5(j) </U></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">___________________, 2022 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVB Securities LLC </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">as Representatives of
the several </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Underwriters to be named in the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">within-mentioned</FONT> Underwriting Agreement </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BofA Securities, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">One Bryant Park New </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">York, New
York 10036 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SVB Securities LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1301 Avenue of the Americas, 12th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Proposed Public Offering by 89bio, Inc.</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, a
securityholder, an officer and/or a director, as applicable, of 89bio, Inc., a Delaware corporation (the &#147;Company&#148;), understands that BofA Securities, Inc. (&#147;BofAS&#148;) and SVB Securities LLC (&#147;SVB Securities,&#148; and,
together with BofAS, the &#147;Representatives&#148;) propose to enter into an Underwriting Agreement (the &#147;Underwriting Agreement&#148;) with the Company, providing for the public offering (the &#147;Public Offering&#148;) of shares of the
Company&#146;s common stock, par value $0.001 per share (&#147;Common Stock&#148;). In recognition of the benefit that the Public Offering will confer upon the undersigned as a securityholder, an officer and/or a director, as applicable, of the
Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreement that, during the period beginning on the
date hereof and ending on the date that is 60 days from the date of the Underwriting Agreement (the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), the undersigned will not, without the prior written consent of the
Representatives, (i)&nbsp;directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or
dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter
acquires the power of disposition (collectively, the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;), or exercise any right with respect to the registration of any of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Securities, or file, cause to be filed or cause to be confidentially submitted any registration statement in connection therewith, under the Securities Act of 1933, as amended, or (ii)&nbsp;enter into any swap or any other agreement or any
transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such swap or transaction is to be settled by delivery of
shares of Common Stock or other securities, in cash or otherwise. If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any issuer-directed Common
Stock the undersigned may purchase in the Public Offering. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, and subject to the conditions below, the undersigned may
transfer the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities without the prior written consent of the Representatives: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a <I>bona fide</I> gift or gifts, <I>provided</I> that (i)&nbsp;the Representatives<B> </B>receive a signed <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each transferee prior to such transfer, (ii)&nbsp;any such transfer shall not involve a disposition for value,
(iii)&nbsp;any such transfer is not required to be publicly filed or reported during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and (iv)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report
regarding such transfers during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by will or intestate succession upon the death of the undersigned, including to the transferee&#146;s nominee
or custodian, <I>provided</I> that (i)&nbsp;the Representatives<B> </B>receive a signed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each transferee
prior to such transfer, (ii)&nbsp;any such transfer shall not involve a disposition for value, (iii)&nbsp;if required, any public filing or report under Section&nbsp;16 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange
Act&#148;) during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that the such transfer is being made pursuant to the circumstances described in this clause, and (iv)&nbsp;no public filings
or reports regarding such transfers shall be otherwise voluntarily effected during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the immediate family of the undersigned or any trust, partnership or similar entity for the direct or
indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, &#147;immediate family&#148; shall mean any relationship by blood, marriage or adoption,
not more remote than first cousin) or if the undersigned is a trust, to any beneficiary of the undersigned (including such beneficiary&#146;s estate), <I>provided</I> that (i)&nbsp;the Representatives<B> </B>receive a signed <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each transferee prior to such transfer, (ii)&nbsp;any such transfer shall not involve a disposition for value,
(iii)&nbsp;any such transfer is not required to be publicly filed or reported during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and (iv)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report
regarding such transfers during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a <FONT STYLE="white-space:nowrap">non-natural</FONT> person, as a distribution to
limited partners, general partners, limited liability company members, stockholders or other equity holders of the undersigned, <I>provided</I> that (i)&nbsp;the Representatives<B> </B>receive a signed <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each transferee prior to such transfer, (ii)&nbsp;any such transfer shall not involve a disposition for value, (iii)&nbsp;any such transfer is not required
to be publicly filed or reported during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and (iv)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the undersigned&#146;s affiliates or to any investment fund or other entity controlled or managed by the
undersigned, <I>provided</I> that (i)&nbsp;the Representatives<B> </B>receive a signed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each transferee prior
to such transfer, (ii)&nbsp;any such transfer shall not involve a disposition for value, (iii)&nbsp;any such transfer is not required to be publicly filed or reported during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and
(iv)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the Company upon exercise of any right in respect of any option granted under any incentive plan of the
Company described in the final prospectus relating to the Public Offering or any document incorporated by reference therein, including the surrender of shares of Common Stock to the Company in &#147;net&#148; or &#147;cashless&#148; exercise of any
option, <I>provided</I>, that (i)&nbsp;the shares of Common Stock received by the undersigned upon exercise continue to be subject to the restrictions on transfer set forth in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement,
(ii)&nbsp;if required, any public filing or report under Section&nbsp;16 of the Exchange Act during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that the filing relates to the exercise of
a stock option, that no shares were sold by the reporting person and that the shares received upon exercise of the stock option are subject to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, and (iii)&nbsp;the undersigned does not
otherwise voluntarily effect any public filing or report regarding such transfers during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to an order of a court of competent jurisdiction or in connection with a qualified domestic order or
divorce settlement, <I>provided</I>, that (i)&nbsp;the Representatives<B> </B>receive a signed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each
transferee prior to such transfer, (ii)&nbsp;if required, any public filing or report under Section&nbsp;16 of the Exchange Act during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that
the such transfer is being made pursuant to the circumstances described in this clause, and (iii)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to a <I>bona fide</I> third party pursuant to a merger, consolidation, tender offer or other similar
transaction made to all holders of Common Stock and involving a Change of Control of the Company and approved by the Company&#146;s board of directors, <I>provided</I>, that (i)&nbsp;in the event that such Change of Control is not completed, the
undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the restrictions contained herein, and (ii)&nbsp;any shares of Common Stock not transferred in such merger, consolidation, tender offer or similar
transaction shall remain subject to the restrictions contained herein. &#147;Change of Control&#148; shall mean the transfer (whether by tender offer, merger, consolation or other similar transaction), in one transaction or a series of related
transactions, to a person or group of affiliated persons (other than an underwriter pursuant to the Public Offering), of the Company&#146;s voting securities if, after such transfer, such person or group of affiliated persons would hold more than
50% of the outstanding voting securities of the Company (or the surviving entity). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, the undersigned may sell shares of Common Stock purchased by the undersigned in the Public Offering or in the open market transactions following the Public Offering if and only if (i)&nbsp;such sales
are not required to be publicly filed or reported during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and (ii)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such sales during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing herein shall prevent the undersigned from establishing a <FONT
STYLE="white-space:nowrap">10b5-1</FONT> trading plan that complies with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (a <FONT STYLE="white-space:nowrap">&#147;10b5-1</FONT> trading plan&#148;) so long as any such plan
does not permit sales of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period; and <I>provided</I> that the establishment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT>
trading plan shall only be permitted if (i)&nbsp;the establishment of such plan is not required to be reported in any public filing or report with the Securities and Exchange Commission, or otherwise and (ii)&nbsp;the undersigned does not otherwise
voluntarily effect any public filing or report regarding the establishment of such plan during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company&#146;s transfer agent and registrar against the transfer of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, except in compliance with the foregoing restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained herein, this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will automatically
terminate and the undersigned will be released from all of his, her or its obligations hereunder upon the earliest to occur, if any, of (i)&nbsp;if the Representatives, on the one hand, or the Company, on the other hand, informs the other, prior to
the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, (ii)&nbsp;the date the Company files an application with the Securities and Exchange Commission to withdraw the registration statement
related to the Public Offering, (iii)&nbsp;the date the Underwriting Agreement is terminated prior to payment for and delivery of the shares of Common Stock to be sold thereunder or (iv)&nbsp;July&nbsp;31, 2022, in the event that the Underwriting
Agreement has not been executed by such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Security Holder <I>(Print exact name)</I></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>(Signature)</I></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If not signing in an individual capacity:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory <I>(Print)</I></P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title of Authorized Signatory<I> (Print)</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>(Indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Common Warrant </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[attached] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[attached] </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d376547dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK PURCHASE WARRANT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89bio, Inc. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant Shares: _______</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">Issue Date: July&nbsp;1, 2022</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS <B>COMMON STOCK PURCHASE WARRANT</B> (the &#147;<U>Warrant</U>&#148;) certifies that, for value received,
_____________ or its assigns (the &#147;<U>Holder</U>&#148;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#147;<U>Issue Date</U>&#148;)
and on or prior to 5:00 p.m. (New York City time) on July&nbsp;1, 2024, (the &#147;<U>Termination Date</U>&#148;) but not thereafter, to subscribe for and purchase from 89bio, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), up to
______ shares (as subject to adjustment hereunder, the &#147;<U>Warrant Shares</U>&#148;) of common stock, $0.001 par value per share, of the Company (&#147;<U>Common Stock</U>&#148;). The purchase price of one share of Common Stock under this
Warrant shall be equal to the Exercise Price, as defined in <U>Section</U><U></U><U>&nbsp;2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;1</U>.
<U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement (the &#147;<U>Underwriting Agreement</U>&#148;), dated June&nbsp;28, 2022, among the Company, BofA
Securities, Inc. and SVB Securities LLC, as representatives of the underwriters named therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;2</U>.
<U>Exercise</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made,
in whole or in part, at any time or times on or after the Issue Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by <FONT STYLE="white-space:nowrap">e-mail</FONT> (or <FONT
STYLE="white-space:nowrap">e-mail</FONT> attachment) of the Notice of Exercise in the form annexed hereto (the &#147;<U>Notice of Exercise</U>&#148;). Within the earlier of (i)&nbsp;two (2) Trading Days and (ii)&nbsp;the number of Trading Days
comprising the Standard Settlement Period (as defined in Section&nbsp;2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of
Exercise by wire transfer or cashier&#146;s check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c) below is specified in the applicable Notice of Exercise. No
<FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company
shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)&nbsp;Trading Day of its receipt of such notice. <B>The Holder and
any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Exercise Price</U>. The
exercise price per share of Common Stock under this Warrant shall be <B>$</B>5.325, subject to adjustment hereunder (the &#147;<U>Exercise Price</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the
prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in part, at such time by means of a &#147;cashless exercise&#148; in which the Holder shall be
entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing <FONT STYLE="white-space:nowrap">[(A-B)</FONT> (X)] by (A), where: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(A)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on a day
that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on a Trading Day prior to the opening of &#147;regular trading hours&#148; (as defined in Rule 600(b) of Regulation NMS promulgated under the
federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either (y)&nbsp;the VWAP</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#147;<U>Bloomberg</U>&#148;) as of
the time of the Holder&#146;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#147;regular trading hours&#148; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two
(2)&nbsp;hours after the close of &#147;regular trading hours&#148; on a Trading Day) pursuant to Section&nbsp;2(a) hereof or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading
Day and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;2(a) hereof after the close of &#147;regular trading hours&#148; on such Trading Day;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(B)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(X)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">=</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree
that in accordance with Section&nbsp;3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section&nbsp;2(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Bid Price</U>&#148; means, for any date, the price determined by the first of the following clauses that applies:
(a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as
reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:00 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or
agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Market</U>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the OTCQB or the OTCQX (or any successors to any of the foregoing). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>VWAP</U>&#148; means, for any date, the price determined by the first of the following clauses that applies:
(a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or
quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or
the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported thereon, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by
an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Mechanics of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be
transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#147;<U>DWAC</U>&#148;) if
the Company is then a participant in such system for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of
(i)&nbsp;two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)&nbsp;the number of Trading Days comprising the Standard
Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#147;<U>Warrant Share Delivery Date</U>&#148;). In the event that the Registration Statement or another registration statement registering the issuance of
Warrant Shares is, for any reason, not effective at the time of the Notice of Exercise, then the Warrant may only be exercised through a cashless exercise. Upon delivery of the Notice of Exercise to the Company, the Holder shall be deemed for all
corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, <I>provided</I> that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i)&nbsp;two (2) Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise to
the Company. As used herein, &#147;<U>Standard Settlement Period</U>&#148; means the standard settlement period, expressed in a number of Trading Days, on the Company&#146;s primary Trading Market with respect to the Common Stock as in effect on the
date of delivery of the Notice of Exercise to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Delivery of New Warrants Upon Exercise</U>. If this
Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the
Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iii. <U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares
pursuant to Section&nbsp;2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iv. <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Warrant Shares Upon
Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i) above pursuant to an
exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#146;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U>&#148;), then the Company shall (A)&nbsp;pay in
cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&#146;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the
number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue multiplied by (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at
the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or promptly deliver to the Holder the
number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a <FONT
STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Company,
evidence of the amount of such loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">v. <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vi. <U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as
may be directed by the Holder; <I>provided</I>, <I>however</I>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment
Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for
<FONT STYLE="white-space:nowrap">same-day</FONT> processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for
<FONT STYLE="white-space:nowrap">same-day</FONT> electronic delivery of the Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vii. <U>Closing of Books</U>.
The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Holder&#146;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the
Holder&#146;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#146;s Affiliates (such Persons, &#147;<U>Attribution Parties</U>&#148;)), would beneficially own in excess of the Beneficial Ownership
Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon
exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial ownership shall be
calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section&nbsp;2(e) applies, the determination of
whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the
Holder&#146;s submission of a Notice of Exercise to the Company shall be deemed to be the Holder&#146;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and
Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and, absent manifest error, the Company shall have no obligation to verify or confirm the accuracy of such
determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this
Section&nbsp;2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&#146;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent
public announcement by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within
one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. As used herein, &#147;<U>Affiliate</U>&#148; shall
mean any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. The
&#147;<U>Beneficial Ownership Limitation</U>&#148; shall be [4.99][9.99]% (or, at the election of the Holder prior to the issuance of the Warrant, 4.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock issuable upon exercise of this Warrant. Notwithstanding the foregoing, in the case of a Holder who immediately prior to the Issue Date beneficially owns in excess of 9.99% of the number of shares of the Common
Stock outstanding at such time, as calculated in accordance with Section&nbsp;13(d) of the Exchange Act, the Beneficial Ownership Limitation shall be 19.99% (the &#147;<U>Maximum Cap</U>&#148;) of the number of shares of Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant; provided, that the Maximum Cap shall only apply to the extent required by Nasdaq Marketplace Rule 5635(b) and if the Maximum Cap is not
applicable then the Warrant shall be fully exercisable. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e) to correct this paragraph (or any
portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;3</U>. <U>Certain Adjustments</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common
Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of reverse stock split) outstanding shares of Common Stock into a
smaller number of shares, or (iv)&nbsp;issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Warrant Shares shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately before such event, and the Exercise
Price shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a) shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or <FONT STYLE="white-space:nowrap">re-classification.</FONT>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a) above, if at any time
the Company grants, issues or sells any rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#147;<U>Purchase Rights</U>&#148;), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is
taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<I>provided</I>, <I>however</I>, that, to the extent that the Holder&#146;s right to participate in
any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such
time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar
transaction) (a &#147;<U>Distribution</U>&#148;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(<I>provided</I>, <I>however</I>, that, to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person,
(ii)&nbsp;the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of
related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the outstanding voting power of the common equity of the Company, (iv)&nbsp;the Company,
directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or
exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a
reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common
Stock or 50% or more of the outstanding voting power of the common equity of the Company (each a &#147;<U>Fundamental Transaction</U>&#148;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each
Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant),
the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#147;<U>Alternate Consideration</U>&#148;) receivable as a result of such
Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Calculations</U>. All calculations under this Section&nbsp;3 shall be made to the nearest
<FONT STYLE="white-space:nowrap">one-hundredth</FONT> of one cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Voluntary Adjustment By Company</U>. Subject to the rules and
regulations of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by
the board of directors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Notice to Holder</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section&nbsp;3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement
of the facts requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall
declare a dividend (or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the Company shall authorize the granting to
all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection with any
reclassification of the Common Stock, any consolidation or merger to which the Company (and all of its Subsidiaries, taken as a whole) is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case,
the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the
holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange; <I>provided</I> that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be
specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of the Subsidiaries, the Company shall
simultaneously file such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice
to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4</U>. <U>Transfer of Warrant</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are
transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name
of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, if any, and this
Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder
shall surrender this Warrant to the Company within three (3) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>New Warrants</U>. This
Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the
Holder or its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by
the Company for that purpose (the &#147;<U>Warrant Register</U>&#148;), in the name of the record Holder hereof from time to time. The Company shall deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of
any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;5</U>. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant
Shares on a &#147;cashless exercise&#148; pursuant to Section&nbsp;2(c) or to receive cash payments pursuant to Section&nbsp;2(d)(i) and Section&nbsp;2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this
Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock
certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on
the next succeeding Trading Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Authorized Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority
to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant
Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid
and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase
the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to
enable the Company to perform its obligations under this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before taking any action which would result in an
adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents, warrants and covenants that, as of the date hereof,
(i)&nbsp;the issued and outstanding Common Stock of the Company is registered pursuant to <U>Section</U><U></U><U>&nbsp;12(b) </U>of the Exchange Act, and listed for trading on the Nasdaq Capital Market; (ii)&nbsp;there is no suit, action,
proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by any Trading Market, or the Commission with respect to any intention by such entity to deregister the Common Stock or prohibit or terminate the
listing of the Common Stock on the Nasdaq Capital Market or any other Trading Market; and (iii)&nbsp;the Company has taken no action that is designed to terminate the registration of Common Stock under the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents, warrants and covenants that, as of the date hereof, (i)&nbsp;it has not entered into any subscription
agreement, side letter or similar agreement or understanding with any investor in connection with such investor&#146;s direct or indirect investment in the Company other than the Warrants; and (ii)&nbsp;the other Common Stock purchase warrants
issued by the Company pursuant to the Underwriting Agreement and the Registration Statement (a)&nbsp;reflect the same Exercise Price as provided herein, and (b)&nbsp;do not contain, and will not be amended to contain, any terms that are materially
more favorable to any such other subscriber thereunder than the terms of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Jurisdiction</U>. All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Underwriting Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of
Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#146;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to
comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall promptly pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to,
reasonable external attorneys&#146; fees of one counsel, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <U>Notices</U>. Any notices, consents, waivers or other document or communications required or permitted to be given or
delivered under the terms of this Warrant must be in writing and will be deemed to have been delivered: (i)&nbsp;upon receipt, if delivered personally; (ii)&nbsp;when sent, if sent by facsimile (<I>provided</I> confirmation of transmission is
mechanically or electronically generated and kept on file by the sending party); (iii) when sent, if sent by <FONT STYLE="white-space:nowrap">e-mail</FONT> (<I>provided</I> that such sent <FONT STYLE="white-space:nowrap">e-mail</FONT> is kept on
file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically generated message from the recipient&#146;s <FONT STYLE="white-space:nowrap">e-mail</FONT> server that such <FONT
STYLE="white-space:nowrap">e-mail</FONT> could not be delivered to such recipient) and (iv)&nbsp;if sent by overnight courier service, one (1)&nbsp;Trading Day after deposit with an overnight courier service with next day delivery specified, in each
case, properly addressed to the party to receive the same. If notice is given by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
facsimile or email, a copy of such notice shall be dispatched no later than the next business day by first class mail, postage prepaid. The addresses, facsimile numbers and <FONT
STYLE="white-space:nowrap">e-mail</FONT> addresses for such communications shall be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">89bio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">142 Sansome
Street, 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Ryan Martins; Shiva Natarajan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Chief Financial Officer; SVP, Finance&nbsp;&amp; Principal Accounting Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: ryan.martins@89bio.com; shiva.natarajan@89bio.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy (for informational purposes only) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&nbsp;&amp; Crutcher LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">555 Mission Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San
Francisco, CA 94105 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> rmurr@gibsondunn.com; bberns@gibsondunn.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Ryan A. Murr; Branden C. Berns </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to a Holder, to its address, facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or
on the books and records of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Or, in each of the above instances, to such other address, facsimile number or <FONT
STYLE="white-space:nowrap">e-mail</FONT> address and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change.
Written confirmation of receipt (A)&nbsp;given by the recipient of such notice, consent, waiver or other communication, (B)&nbsp;mechanically or electronically generated by the sender&#146;s facsimile machine containing the time, date and recipient
facsimile number or (C)&nbsp;provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iv)&nbsp;above,
respectively. A copy of the <FONT STYLE="white-space:nowrap">e-mail</FONT> transmission containing the time, date and recipient <FONT STYLE="white-space:nowrap">e-</FONT> mail address shall be rebuttable evidence of receipt by <FONT
STYLE="white-space:nowrap">e-mail</FONT> in accordance with clause (iii)&nbsp;above. Notwithstanding anything in this Warrant to the contrary, the Company shall not publicly disclose the name of Holder or any of its Affiliates, or include the name
of Holder or any of its Affiliates in any press release or in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of Holder, except (i)&nbsp;as required by the federal or state securities laws
and (ii)&nbsp;to the extent such disclosure is required by law, rules or regulation of any applicable governmental authority or self-regulatory organization (including Nasdaq or other stock exchange). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this
Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such
liability is asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <U>Successors and Assigns</U>. Subject to
applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The
provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in
such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <U>Headings</U>. The
headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">******************** </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page Follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>89BIO, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Rohan Palekar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TO:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">89bio, Inc. (the &#147;Company&#148;)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of
the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) Payment shall take the form of (check applicable box): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[ ] in lawful money of the United States; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">The Warrant Shares shall be delivered to the following DWAC Account Number:</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By its delivery of this Notice of Exercise, the undersigned represents and warrants to the Company that in giving effect to
the exercise evidenced hereby the Holders will not beneficially own in excess of the number of shares of Common Stock permitted to be owned under Section&nbsp;2(e) of the Warrant to which this notice relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[SIGNATURE OF HOLDER] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name of Investing Entity:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><I>Signature of Authorized Signatory of Investing Entity</I>:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name of Authorized Signatory:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title of Authorized Signatory:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSIGNMENT FORM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(Please Print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(Please Print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phone Number:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email Address:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: _______________ __, ______</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holder&#146;s Signature:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Holder&#146;s Address:</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>d376547dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89BIO, INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [&#149;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject to adjustment) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Warrant No. [&#149;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Original Issue Date: July&nbsp;1, 2022</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">89bio, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [&#149;] or its permitted registered assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the Company up to
a total of [&#149;] shares of common stock, $0.001 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant Shares</B>&#148;) at an
exercise price per share equal to $0.001 per share (as adjusted from time to time as provided in <U>Section</U><U></U><U>&nbsp;9</U> herein, the &#147;<B>Exercise Price</B>&#148;), upon surrender of this
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to
time on or after the date hereof (the &#147;<B>Original Issue Date</B>&#148;), and subject to the following terms and conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1
DEFINITIONS.</B> For purposes of this Warrant, the following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148;
means any Person directly or indirectly controlled by, controlling, or under common control with, a Holder, but only for so long as such control shall continue. For purposes of this definition, &#147;control&#148; (including, with correlative
meanings, &#147;controlled by,&#148; &#147;controlling&#148; and &#147;under common control with&#148;) means, with respect to a Person, possession, direct or indirect, of (a)&nbsp;the power to direct or cause direction of the management and
policies of such Person (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b)&nbsp;at least 50% of the voting securities (whether directly or pursuant to any option, warrant, or other
similar arrangement) or other comparable equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Commission</B>&#148; means the United States Securities and
Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the Common Stock is
primarily listed and quoted for trading, which, as of the Original Issue Date, shall be The Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
&#147;<B>Registration Statement</B>&#148; means the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-254684),</FONT> which was filed, and became effective,
on April&nbsp;23, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market
is open for trading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Transfer Agent</B>&#148; means Computershare Trust Company, N.A., the Company&#146;s transfer agent and
registrar for the Common Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>VWAP</B>&#148; means, for any date, the price
determined by the first of the following clauses that applies: (i)&nbsp;if the Common Stock is then listed or quoted on a national securities exchange or other trading market, the daily volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on the Principal Trading Market as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (ii) if the Common Stock is then listed or quoted for
trading and neither OTCQB nor OTCQX is the Principal Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (iii)&nbsp;if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &#147;<B>Pink Sheets</B>&#148; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of
reporting prices), the most recent bid price per share of the Common Stock so reported, or (iv)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2</B> <B>ISSUANCE OF
SECURITIES; REGISTRATION OF WARRANTS</B>. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement.
Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not
&#147;restricted securities&#148; under Rule 144 promulgated under the Securities Act. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B><U>Warrant Register</U></B>&#148;), in the
name of the record Holder (which shall include the initial Holder or, as the case may be, any registered assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of
this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3</B> <B>REGISTRATION OF TRANSFERS</B>. Subject to compliance with all applicable securities laws, the Company shall, or will cause its
Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to
purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the
remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and
obligations in respect of the New Warrant that the Holder has in respect of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue, and deliver at the Company&#146;s own expense any New Warrant under this <U>Section 3</U>. Until due presentment
for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder of this Warrant for all purposes and the Company shall not be affected by any notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4 EXERCISE AND DURATION OF WARRANTS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by
<U>Section</U><U></U><U>&nbsp;10</U> of this Warrant at any time and from time to time on or after the Original Issue Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The
Holder may exercise this Warrant by delivering to the Company (i)&nbsp;an exercise notice, in the form attached as <U>Schedule 1</U> hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise
Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a &#147;cashless exercise&#148; if so indicated in the Exercise Notice pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below), and the
date on which the last of such items is delivered to the Company (as determined in accordance with the notice provisions hereof) is an &#147;<B>Exercise Date.</B>&#148; The Holder shall not be required to deliver the original Warrant in order to
effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5 DELIVERY OF WARRANT SHARES.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant, the Company shall promptly (but in no event more than three (3)&nbsp;Trading Days after the Exercise Date),
upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company
(&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program (the &#147;<B>FAST Program</B>&#148;) or if the certificates or book
entry position are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate or book entry position, registered in the Company&#146;s
share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#147;<B>Person</B>&#148;)
permissibly so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC
account or the date of delivery of the certificates or book entry position evidencing such Warrant Shares, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If by
the close of the third Trading Day after the Exercise Date, the Company fails to credit the Holder&#146;s balance account with DTC for such number of Warrant Shares to which the Holder is entitled, and if after such third Trading Day and prior to
the receipt of such Warrant Shares, the Holder purchases (in an open market transaction, provided such purchases shall be made in a commercially reasonable manner at prevailing market prices) shares </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
&#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;), then the Company shall, within two Trading Days after the Holder&#146;s request, in the Holder&#146;s sole discretion, either (i)&nbsp;pay in cash to the Holder an amount equal to
the Holder&#146;s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company&#146;s obligation to deliver such Warrant Shares shall terminate, or
(ii)&nbsp;(A) pay in cash to the Holder the amount, if any, by which (1)&nbsp;the Holder&#146;s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock purchased in the <FONT
STYLE="white-space:nowrap">Buy-In</FONT> exceeds (2)&nbsp;the product of (x)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue, times (y)&nbsp;the price at which the
sell order giving rise to such purchase obligation was executed (assuming such sale was executed on commercially reasonable terms at prevailing market prices and, if the sale was executed in multiple transactions, the volume weighted average price),
and (B)&nbsp;at the option of the Holder, either (1)&nbsp;reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or
(2)&nbsp;deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. The provisions of this <U>Section</U><U></U><U>&nbsp;5(b)</U> shall
be the only remedy available to the Holder in the event the Company fails to deliver to the Holder the required number of Warrant Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> and a
<FONT STYLE="white-space:nowrap">Buy-In</FONT> occurs. Irrespective of whether there is a <FONT STYLE="white-space:nowrap">Buy-In,</FONT> no remedy shall be available, notwithstanding the requirements of <U>Section</U><U></U><U>&nbsp;5(a)</U>,
unless and until the Company fails to deliver to the Holder the required number of Warrant Shares by the close of the third Trading Day after the Exercise Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to <U>Section</U><U></U><U>&nbsp;5(b)</U>, the Company&#146;s obligations to issue and deliver
Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in <U>Section</U><U></U><U>&nbsp;11</U> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the
same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach
by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company
to the Holder in connection with the issuance of Warrant Shares. Subject to <U>Section</U><U></U><U>&nbsp;5(b)</U>, nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver certificates or a book entry position representing shares of Common Stock upon exercise of the
Warrant as required pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6</B> <B>CHARGES, TAXES AND EXPENSES</B>. Issuance and delivery of a book entry
position for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of
the issuance of such or book entry shares, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the
registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring
this Warrant or receiving Warrant Shares upon exercise hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7</B> <B>REPLACEMENT OF WARRANT</B>. If this Warrant is mutilated, lost, stolen, or
destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the
Company of such loss, theft, or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other
reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to
the Company as a condition precedent to the Company&#146;s obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8 RESERVATION OF WARRANT SHARES.</B>
The Company covenants that it will at all times while this Warrant is outstanding reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue
Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are then issuable and deliverable upon the exercise of this Warrant, free from preemptive rights or any other contingent purchase rights of persons
other than the Holder (taking into account the adjustments and restrictions of <U>Section&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in
accordance with the terms hereof, be duly and validly authorized, issued and fully paid, and nonassessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided
herein without violation of any applicable law or regulation or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9 CERTAIN ADJUSTMENTS</B>. The number of Warrant Shares issuable upon exercise of this Warrant is subject to adjustment from time to time
as set forth in this <U>Section</U><U></U><U>&nbsp;9</U><U>.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while
this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date or as amended, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into
a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the number of Warrant Shares then underlying this Warrant
shall be divided by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after
such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the number of Warrant Shares shall be recomputed accordingly as of the
close of business on such record date and thereafter the Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii) of this paragraph shall
become effective immediately after the effective date of such subdivision or combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If the
Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common Stock covered by the
preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv)&nbsp;cash or any other asset (in each case, &#147;<B>Distributed Property</B>&#148;), then, upon any exercise of this Warrant that occurs after the
record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property
that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard to any limitation on exercise
contained therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects
any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity or the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at
least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related
transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock who tender shares representing more than 50% of the voting power of the capital stock of the Company and the
Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the
stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by
<U>Section</U><U></U><U>&nbsp;9(a)</U> above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount
and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then
issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not effect any Fundamental Transaction in which the Company is not the
surviving entity or the Alternate Consideration includes securities of another Person unless (x)&nbsp;the Alternate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Consideration is solely cash and the Company provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below or (y)&nbsp;prior
to, simultaneously with or promptly following the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder, such
Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions
analogous of a Fundamental Transaction type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Calculations</U>. All calculations under this <U>Section</U><U></U><U>&nbsp;9</U>
shall be made to the nearest share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this
<U>Section</U><U></U><U>&nbsp;9</U>, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such
adjustment, including a statement of the adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the
facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Transfer Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii)&nbsp;enters
into any definitive agreement contemplating or soliciting stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice
and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the applicable
record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; <I>provided</I>, <I>however</I>, that the failure to deliver such notice or any defect therein shall not
affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company enters into any definitive agreement contemplating or solicits stockholder approval for any
Fundamental Transaction contemplated by <U>Section</U><U></U><U>&nbsp;9(c)</U>, other than a Fundamental Transaction under clause (iii)&nbsp;of <U>Section</U><U></U><U>&nbsp;9(c)</U>, the Company shall deliver to the Holder a notice of such
Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is consummated. Holder agrees to maintain any information disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;9(f)</U> in confidence until such
information is publicly available and shall comply with applicable law with respect to trading in the Company&#146;s securities following receipt any such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10 PAYMENT OF EXERCISE PRICE.</B> Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion,
satisfy its obligation to pay the Exercise Price through a &#147;cashless exercise,&#148; in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">where: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>X</B>&#148; equals the number of Warrant Shares to be issued to the Holder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Y</B>&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>A</B>&#148; equals the last VWAP immediately preceding the time of delivery of the Exercise Notice giving rise to the applicable
&#147;cashless exercise,&#148; as set forth in the applicable Exercise Notice (to clarify, the &#147;last VWAP&#148; will be the last VWAP as calculated over an entire Trading Day such that, in the event that this Warrant is exercised at a time that
the Principal Trading Market is open, the prior Trading Day&#146;s VWAP shall be used in this calculation); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>B</B>&#148;
equals the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144
promulgated under the Securities Act, it is intended, understood, and acknowledged that the Warrant Shares issued in a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the
Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in <U>Section</U><U></U><U>&nbsp;12</U> (payment of cash in lieu of fractional shares), in no event will the exercise of
this Warrant be settled in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11 LIMITATIONS ON EXERCISE.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained in any Section herein, the Company shall not effect any exercise of this Warrant, and
the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect to such exercise, would cause (i)&nbsp;the aggregate number of shares of Common Stock
beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act, to exceed [4.99][9.99]% (or, at
the election of the Holder prior to the issuance of the Warrant, 4.99%) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii)&nbsp;the combined voting power of the securities of the
Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to exceed 9.99% of the
combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding
shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed
with the Commission prior to the date hereof, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other notice by the Company or its transfer agent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3)&nbsp;Trading Days confirm in writing or by electronic
mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the maximum percentage to any other
percentage specified not in excess of 19.99% (the &#147;<B>Maximum Cap</B>&#148;) in such notice; provided that any such increase will not be effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after such
notice is delivered to the Company; provided, that the Maximum Cap shall only apply to the extent required by Nasdaq Marketplace Rule 5635(b) and if the Maximum Cap is not applicable then the Warrant shall be fully exercisable. For purposes of this
<U>Section</U><U></U><U>&nbsp;11(a)</U>, the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated
with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of this Warrant by the Holder and (y)&nbsp;exercise or conversion of the
unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power (including, without limitation, any securities
of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or
exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates
and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This <U>Section</U><U></U><U>&nbsp;11</U> shall not restrict the number of shares of Common Stock that a Holder may receive or
beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in <U>Section</U><U></U><U>&nbsp;9</U> of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12 NO FRACTIONAL SHARES.</B> No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any
fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the last VWAP immediately
preceding the time of delivery of the applicable Exercise Notice) for any such fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13 NOTICES.</B> Any and all notices
or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)<U></U>&nbsp;the date of transmission, if such notice or
communication is delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified below prior to 4:00 P.M., New York City time, on a Trading Day, (ii) the next Trading Day
after the date of transmission, if such notice or communication is delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the e-mail </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
address specified below on a day that is not a Trading Day or later than 4:00 P.M., New York City time, on any Trading Day, (iii)<U></U> the second Trading Day following the date of mailing, if
sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The e-mail address for purposes of providing
notice hereunder is: Ryan.Martins@89bio.com and Shiva.Natarajan@89bio.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14 WARRANT AGENT.</B> The Company shall initially serve as
warrant agent under this Warrant. Upon ten (10) days&#146; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged, or any corporation resulting from any
consolidation to which the Company or any new warrant agent shall be a party, or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor
warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last
address as shown on the Warrant Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15 MISCELLANEOUS.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a Stockholder</U>. The Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to
vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this
Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance
or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In
addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are
asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except and to the extent as waived or consented to
by the Holder, the Company shall not by any action, including, without limitation amending its articles of organization or effect any reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other
voluntary action to avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon
the exercise of this Warrant, and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to
perform its obligations under this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable securities laws,
this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the
benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable
right, remedy, or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take
any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT, AND
INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE STATE OF NEW YORK, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN
(INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH
COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT
DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT
IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant, and shall not be deemed to limit
or affect any of the provisions hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree
upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its
authorized officer as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>89BIO, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SCHEDULE 1 </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF EXERCISE NOTICE </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be
executed by the Holder to purchase shares of Common Stock under the Warrant] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned is the Holder of Warrant No. ______ (the &#147;<B>Warrant</B>&#148;) issued by Cogent
Biosciences, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Holder intends that payment of the Exercise Price shall be made as (check one): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Cashless Exercise</B>&#148; under Section&nbsp;10 of the Warrant </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $______ in immediately available
funds to the Company in accordance with the terms of the Warrant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in
accordance with the terms of the Warrant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving
effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be
owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Holder:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>d376547dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g376547g0701000107995.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Client: 26925-00009 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;30, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">89bio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">142 Sansome Street, Second Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California 94104
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>89bio, Inc.</I> <I> </I></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File
No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;333-254684)</FONT></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have examined the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-254684</FONT> (the &#147;<U>Registration Statement</U>&#148;), of 89bio, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), filed with the Securities and Exchange Commission (the
&#147;<U>Commission</U>&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), in connection with the offering by the Company of (i) 18,675,466 shares of the Company&#146;s common stock (the
&#147;<U>Common Stock</U>&#148;), par value $0.001 per share (the &#147;<U>Shares</U>&#148;), (ii) <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the &#147;<U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</U>&#148;) to
purchase an aggregate of 7,944,252 shares of Common Stock (the &#147;<U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares</U>&#148;) and (iii)&nbsp;warrants (the &#147;<U>Warrants</U>&#148;) to purchase an aggregate of 13,309,859
shares of Common Stock (the &#147;<U>Warrant Shares</U>&#148;). The Shares, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Warrants are being sold pursuant to an underwriting agreement, dated June&nbsp;28, 2022 (the
&#147;<U>Underwriting Agreement</U>&#148;), among the Company and the representatives of the underwriters named therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In arriving at the opinion
expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of specimen Common Stock certificates, form of
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, form of Warrant and such other documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable
to enable us to render the opinions set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents
submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the
foregoing, we are of the opinion that (i)&nbsp;the Shares have been duly authorized and, when issued and delivered pursuant to the Underwriting Agreement against payment of the consideration set forth therein, will be validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable,</FONT> (ii)&nbsp;provided that the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly executed and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g376547g0701001114973.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g376547g0701000108276.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 30, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivered by the Company and duly delivered to the purchaser thereof against payment therefor, then the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, when issued and sold as
described in the Registration Statement, assuming a sufficient number of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares are at the time available for issuance, will be a valid and legally binding obligation of the Company,
enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting creditors&#146; rights generally and by
general equitable principles (regardless of whether such enforceability is considered in a proceeding at law or in equity) and implied covenants of good faith and fair dealing, (iii)&nbsp;the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant Shares, when issued upon a valid exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in accordance with their terms, will have been duly authorized and validly issued and will be fully paid and <FONT
STYLE="white-space:nowrap">non-assessable,</FONT> (iv)&nbsp;provided that the Warrants have been duly executed and delivered by the Company and duly delivered to the purchaser thereof against payment therefor, then the Warrants, when issued and sold
as described in the Registration Statement, assuming a sufficient number of Warrant Shares are at the time available for issuance, will be a valid and legally binding obligation of the Company, enforceable against the Company in accordance with its
terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting creditors&#146; rights generally and by general equitable principles (regardless of whether such
enforceability is considered in a proceeding at law or in equity) and implied covenants of good faith and fair dealing, and (v)&nbsp;the Warrant Shares, when issued upon a valid exercise of the Warrants in accordance with their terms, will have been
duly authorized and validly issued and will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the filing of this
opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption &#147;<U>Legal Matters</U>&#148; in the Registration Statement and the prospectus that forms a part thereof. In giving these
consents, we do not thereby admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the Rules and Regulations of the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Gibson, Dunn&nbsp;&amp; Crutcher LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>etnb-20220628.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 7/1/2022 3:11:12 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:etnb="http://www.89bio.com/20220628"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.89bio.com/20220628"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="etnb-20220628_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="etnb-20220628_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>etnb-20220628_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 7/1/2022 3:11:12 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>etnb-20220628_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 7/1/2022 3:11:12 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="etnb-20220628.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g376547g0701000107995.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g376547g0701000107995.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  E8# 2(  A$! Q$!_\0
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MJ%4$XS]YB#SVYKMJ* ,[3(I8KO5"\+1I)<^9&2<[AY: D>G*FBM&B@ HHHH
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@6E#)(BC:&8_,&<YY_P!EE'_ :V: "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g376547g0701000108276.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g376547g0701000108276.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 ,$# 2(  A$! Q$!_\0
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MGBL_6/#4&LD:KI=QY-VR[E=#\LGI^-9$M_>ZWX#ODG!:YM)0LA Y8 @G\?\
M"IY8SM;;2Z[%<SA>^^MGW-S18;O7+)=2U&YG59\F*WAD**BYXZ<D_6J=_?WG
MA75[;S;F6YTNY.TB8[FB/?#=?>M?PG<)<>%[$H0=D>Q@.Q'%8WQ$Q+I]C;(-
MTTMQA%'4\$?U%*&M;D:T'/2ESIZD_BX:C ;2?2[RX6::3;Y2O\K84MP/P_&M
M30-;AUW3MX.R=1MFC!P5/M[5%J"&*Y\/QL?F6?:?J(FK)\0:7<:+J']OZ0O0
M_P"DPCHP[G%)*,XJ#WZ,;<HR<^G5&GH\,ZZYJB2WMS+';NBQ))(2 &7)SZ]:
MW+B'SK=X_,>/</O(V&'T-8'AC4(M4O-5O8<A)7B.#U!$8!'YUT9Z'Z5E534[
M/R-:=G"Z.)\)+=:S:W<EWJ5\S13>6NV8C Q5G4-2U#PM?6[7-PUYID[;2T@'
MF1'ZCK4?P]_X\-0_Z^C_ "%+\0Y%;2;6T4;IYK@;%'4X!_Q%=+2>(Y&M#G5U
M0YUN.\;W-S9Z?;7EE>3PM)($/EN0I4@G.*Z:V@\NS6+S)7RO+NY+'/O7(^-H
M'@\):<C\F&2-7/N$(KLH'5[>)U.59 0?PK&:7LHV[LUA_$E?R,#2;2::]U:*
M:_O'2*;RHLS'*J5#?GSUK$TK7KW2=7DAU2>6:PFF>**>0YV,K$?_ *ZZ;13N
MOM9D'*M>;0?HB@_K5&RTNVUC0KVTN%RK7D^UAU4[SR*M2BK\RTT(<9.W*]=2
MSXH$RZ,]U:W<T,L97:T4A (+ <CH>M5O$]M=VNCQR6%]=I<*Z1+^^/S[FQS[
M\]:YV34+S2[&Y\.ZGEF!3[-+_>&\<?2NP\2_\@Z#_K\@_P#1@HY7!Q6^OW[!
MS*:DROX8U[^U+9K6[_=ZA;_+*C<%L?Q?XT0V\R^+I83>W36Z6ZSK$921N+$?
MEQTJIXGT.<3KK>DY2^@Y=5_Y:#_&CPYK":WKDETJE'%DB2)Z,';-)Q3BZD-O
MR&I--0EO^9U=%%%<QTF=JVCV>LP+%=(<J<I(IPR'V-5#IVI+;M9G5]\;J4WO
M;@N >.N?Z445:F[6,Y16Y)IFA?V1I#6%I=OEF+"1T!VYZ\5'H?AYM"CEB@OF
MDCD)8J\8X;&,]:**3J2=]=QJG%6LMBO;^%Y[74Y]1AU61;B?/F9A!!S[9J[8
M:!#9ZC)J,TTEU>R#!EDP-H] !THHINK-[L%3BNA!!HUWIJO;V.IE+>1B422$
M.8\G^$Y%7M,TFVTJQ-K$"ZN2TC/R9&/4FBBASDUJ*,$F9\6@-I4TDNE7C6\,
MK9:W=-Z ^HY!%6;?1$_M!=1OIVN[I!B(LNU(_HOK[T44W4D]1*$;V%U+2)M1
MO+:X6^:#[,^^-1&#\V,9///%:8&8MLF'.,-QP?PHHJ')NR+44M3,TC1H-&FO
M?LQ/E7$@D$>/N<=![5HW"220,D,OE.1P^W=C\***')MW8**2LC TSPO<:/YH
ML]6=5E.YP\(;GUZU>M]!@COQ?W4LEY=@81Y<83_=4<"BBKE5F]6Q1IQ6B1;U
M+3[?5+&2SN5W1/Z=0>Q%95IHVHV4*V4.M/\ 9U&%W0 NH] <_P!***49R2MT
M%**O<U+:Q2RL/LMHQ3 .)&^8ECR6/J<U7T?29=)65#>-/'([2%60 AF.2<_T
MHHI<SMZE<JOZ#=<T2VUFWC$OR2PN'CE R1@\CZ&G:SI4FKQ1Q"[:WC1Q(0J
MDL#D<T44*<E;R$X1=_,T(5D2%5ED\QP.7"XS^%9MEHEOI^MW5];_ "?:8P'B
9 X# ]1]?2BBDI-7MU&TG:YK9HHHI%'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g376547g0701001114973.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g376547g0701001114973.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  9 ?T# 2(  A$! Q$!_\0
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M%G=AK6$2^:\1$4F<\*W<\<TO]B:4TT<WV.'>CEU./XLYSCOR*T#C&#C!XYH
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M0V_,, =C1++XP^S23>;<+ET3:( 2B8/S *I)).,^E=CI'_(+A_X%_P"A&KM
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/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140349962807696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001785173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 28,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">89bio, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4946844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">142 Sansome Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Second Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">432-9270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ETNB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>d376547d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="etnb-20220628.xsd" xlink:type="simple"/>
    <context id="duration_2022-06-28_to_2022-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001785173</identifier>
        </entity>
        <period>
            <startDate>2022-06-28</startDate>
            <endDate>2022-06-28</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-06-28_to_2022-06-28">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-06-28_to_2022-06-28"
      id="Hidden_dei_EntityCentralIndexKey">0001785173</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-06-28_to_2022-06-28">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-06-28_to_2022-06-28">2022-06-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-06-28_to_2022-06-28">89bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-06-28_to_2022-06-28">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-06-28_to_2022-06-28">001-39122</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-06-28_to_2022-06-28">36-4946844</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-06-28_to_2022-06-28">142 Sansome Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-06-28_to_2022-06-28">Second Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-06-28_to_2022-06-28">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-06-28_to_2022-06-28">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-06-28_to_2022-06-28">94104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-06-28_to_2022-06-28">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-06-28_to_2022-06-28">432-9270</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-06-28_to_2022-06-28">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-06-28_to_2022-06-28">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-06-28_to_2022-06-28">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-06-28_to_2022-06-28">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-06-28_to_2022-06-28">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-06-28_to_2022-06-28">ETNB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-06-28_to_2022-06-28">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-06-28_to_2022-06-28">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2022-06-28_to_2022-06-28">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M876Z&^#Z6BG[?N(>_:LW-Y-_ 5!+ P04    " !@I]Y4GZ ;\+$"  #B#
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M#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
M   ( &"GWE0<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L)
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !@I]Y4!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M &"GWE3#V@O;[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( &"GWE297)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 8*?>5 *:
M+!1X!   Q1$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( &"GWE2?H!OPL0(  .(,   -
M  "  ;L,  !X;"]S='EL97,N>&UL4$L! A0#%     @ 8*?>5)>*NQS
M$P(   L              ( !EP\  %]R96QS+RYR96QS4$L! A0#%     @
M8*?>5!PX9>H_ 0  / (   \              ( !@!   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( &"GWE0D'INBK0   /@!   :              "
M >P1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &"G
MWE1ED'F2&0$  ,\#   3              "  =$2  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  !L4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d376547d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d376547d8k.htm">d376547d8k.htm</File>
    <File>d376547dex11.htm</File>
    <File>d376547dex41.htm</File>
    <File>d376547dex42.htm</File>
    <File>d376547dex51.htm</File>
    <File>etnb-20220628.xsd</File>
    <File>etnb-20220628_lab.xml</File>
    <File>etnb-20220628_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d376547d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d376547d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "etnb-20220628_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "etnb-20220628_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "etnb-20220628.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "etnb",
   "nsuri": "http://www.89bio.com/20220628",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d376547d8k.htm",
      "contextRef": "duration_2022-06-28_to_2022-06-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d376547d8k.htm",
      "contextRef": "duration_2022-06-28_to_2022-06-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.89bio.com//20220628/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193125-22-186433-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-186433-xbrl.zip
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M4ZRG#:JOL?6=\Q$%J<<MHVS)=*N$*J("YF \XQ+N$QXJ GH"1$U.:[%W9E[
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MR!\Q1@?UP501+:X780Q(_L<#V+O+GL@MOKWF0"8]!2_N6:3:J5N-W=69Y$J
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M#6:$!+_*^%U=!L0!O\L;TK%"GQ8FQW<7I#X:Q,U"MGYJZI_#9$/!*)>@JL1
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M<>F8R9+PP:R*JO/!!+U:I>-%4-K#.BD %#3'4$2>2[K,!Q.(08 W)F+HDX%
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M-EKBPN.'W9-UQ#M.?MWWW:QWLFQWLYL&*[8W#]RT<_5W8*GQ7;!C(!II@_^
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M:W!^!X\>'?6EZ@B1XQYE7I5,IV"/4SS'PT37O.#Q_L%0$;Z+&YVB@T%J=-6
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M?6Y)C*IKSTN#TX8=07*88"^ _Y!^0YVP;HTHI;SE(D576R-;UL<./B]27S/
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MR879;^,MF88UI',,N/HC-T2HNTM 8,(I=^=PD9H6>=!X1"UU'CW<?RG$3X)
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M/.>X6O-[(-2"WVT0\-F/(. M'@D^$^\X0W,URX5N1(6/V#Z+G!CBW(^'*'K
M<(L%JUOJ*K^BBDT<U?NDGB7_BG[+RPD<#>Z)<1^P!%_Y&DK1'A%:&IBCZ(0V
M#\-K=GT2=7S@(T_VN<K3Z1,MR&RGI]H!Q/&(H"3J79&^I\!;N\?%0$&<:0HS
MT'Y6>Z@*'QSR-<2.WD<9'/CWC+I:JIEC/Z2)O=@7\0Q_F)]X(F4,^JDXJCC'
M");GN2]B<,\K+5>K+_.LT$S$"]#%,/O!ZTKYZ)4W#.D,8SG<D@01+Q6R7U;3
MK*8C0#_"NXN3E$LBX!?M1VK.AJ"AY'>1R0 &%&9E&1QI[@!_>W<]42&G,ET*
M#)6=*VN3Q*EL*FDB'CQ-[CQ9#E%QRJ]-6R8QEF4EZP$NQ^&VQ>#RP;3+!7@+
M)(7@W0H0J3S'UEC83*A'*YAN4!KUQ7$3>L^.+N@,/\VIP;>39EF%*)F4V#)
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M?TR\OGZ?9HTVY?8$5E4W@TC+3.B5=(*-=#V:@5&#<L$)/$*++%PS)P\C9,2
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M._88"O,M&UBG@I>^HJHGL>G"B&:O1@FO4\U I"8$2 8D';HZMK253E_8@^9
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M%4!<1:-DG.;)*$KS"/9T!N !(.-VX"_Y#V/!HXU!#S] 673R63G%XGUMTZ:
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M5JUJ0<L0WH'9MP*V(IV:-ZRO*9;!VM<%7$'..IBH;")Q8I$0C'M532J^N!!
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MOAGM254KY_GV'8UVO['A2<$%*_-XY1Z?TN-]5$V17;/B''><N&^,4]F:$8(
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MBI.:U*]<W:6)V<24 XAS_61=/YBQEX$M@I%%>(MZ2F=@\273A;5HR>MK'=?
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M'JAPIRUB[ [)QCS^)L8 0UZBNX6M+'2VN! MCVY#AH6-3CO\1'U7]MBBU\[
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MOF=&(4@\S/>M.B(&6'UUER67XOW%ANTH%=4?%R"/D%10.0KF)A [LI* SR:
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MY_*S2%"%BG%_58O4\^\6J3L'G_GQ#S[U7I\[[0277!/?41:(=$^##4VXR(T
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MR\,J3%JV#%) 4S86;$7;0LK6^J?K%Y&=2FQGK4*4-/$P;Y^^EG09!=J.$-Y
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M*<*'K'&+8'>X:X5Q25>E8+<6+O>M6C$,P3/\8(S$:10I S+_[XHRXC<;!Z-
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M=AL7Y1U7:DO_=:%\%\W^QH[:\S]02P,$%     @ 8*?>5$KT$IW8!   ^2T
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M[&AJY=KJ0BOWZYB]]XP9+@:DFDF5EW: %8:NG.,4O^K*]$2$7PE5=:)?L>\
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MV0=P\<C?4$L! A0#%     @ 8*?>5(.$)^AB$@  \W0   X
M ( !     &0S-S8U-#=D.&LN:'1M4$L! A0#%     @ 8*?>5$+M5'7:G@
M F(# !               ( !CA(  &0S-S8U-#=D97@Q,2YH=&U02P$"% ,4
M    " !@I]Y45U5FIP5   #K-@$ $               @ &6L0  9#,W-C4T
M-V1E>#0Q+FAT;5!+ 0(4 Q0    ( &"GWE0^:,O(X#@  /(! 0 0
M      "  <GQ  !D,S<V-30W9&5X-#(N:'1M4$L! A0#%     @ 8*?>5#-S
M@.G3"0  =2,  !               ( !URH! &0S-S8U-#=D97@U,2YH=&U0
M2P$"% ,4    " !@I]Y4+/1L6CX#  !)"P  $0              @ '8- $
M971N8BTR,#(R,#8R."YX<V102P$"% ,4    " !@I]Y4G:]/"Z<&  "D20
M%0              @ %%. $ 971N8BTR,#(R,#8R.%]L86(N>&UL4$L! A0#
M%     @ 8*?>5$KT$IW8!   ^2T  !4              ( !'S\! &5T;F(M
F,C R,C V,CA?<')E+GAM;%!+!08     "  ( /D!   J1 $    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
